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7I. Introduction
Multiple sclerosis (MS) is a chronic inflammatory and neurodegenerative disease of
the  central  nervous  system  characterized  by  inflammation,  demyelination  and  axonal
degeneration (Trapp et al., 1998). At young age, in the caucasian race, it is the third of the
most frequent neurological diseases in the temperate zone (Compston & Coles, 2008). 
The name of multiple sclerosis comes from the plaques, which are visible at several
different places of the nervous system (multiple). The touch of the plaques is stiffer than that
of the normal brain tissue (sclerosis).
I.1. History of MS
The first case in the history of MS was described in  Augustus d'Esté's diary (1794-
1848)  (Landtblom  et  al.,  2010).  He  was  the  grandson  of  King  George  III  of  England.
Augustus d'Esté's first symptoms appeared after an infection of rubeola in 1822. He reported
transient  failure  of  vision,  which  was  most  likely a  bilateral  optic  neuritis.  Later  he  felt
weakness and numbness in his legs for several weeks. Few years later, he got paraparesis,
sphincter incontinence, urinary problems and impotence. Just by looking at his diary,  it  is
obvious that  Augustus d'Esté's handwriting was barely readable in 1848 due to his intention
tremor. Few weeks later, his hand got palsy, and he died.
The first medical description of MS is associated with Jean-Martin Charcot's name
(1825-1893) (Clanet, 2008). Charcot was a French neurologist and a professor of anatomical
pathology.  By  the  integration  of  previous  reports  and  his  own  clinical  and  pathological
observations, he dubbed the disease sclérose en plaques in 1868. Charcot observed cognition
symptoms, too. He described his patients as having a "marked enfeeblement of the memory"
and "conceptions that formed slowly". 
8I.2. Epidemiology of MS
Since  MS  is  a  rare  disease  in  the  whole  population,  the  common  mortality  and
morbidity  data  are  not  useable  for  the  examination  of  its  epidemiology  and  for  the
determination  of  its  geographical  distribution.  There  are  two  factors  which  describe  the
frequency of the disease: prevalence and incidence. Prevalence is the number of cases with a
disease per 100,000 people in a certain place and time. Incidence is the number of new cases
with a disease within a year. 
In the world, approximately 2.5 million people have MS. The disease has a north-
south gradient (Simpson et al., 2011). Close to the equator, MS occurs at extremely low level.
Earlier studies showed that in case of certain ethnic groups, the prevalence of MS is markedly
low, despite they are living in countries, in which MS is common. These ethnic groups include
the Sami or the Lapps of northern Scandinavia, the Inuits in Canada, and the Maoris of New
Zealand. The higher prevalence of MS in Northern Europe, North America,  Australia and
New Zealand (Alla & Mason, 2014) suggests that MS may have been carried around the
world by the European colonists. The origin of the disease is suggested to be in the Viking
populations. 
As  regards  the  prevalence  of  MS,  Hungary  is  a  medium-risk  country.  The  first
epidemiological study in Hungary on MS was conducted in 1961 by Lehoczky & Halasy-
Lehoczky. According to this study, the crude prevalence of MS was 20/100,000. Pálffy et al.
reported that  the prevalence of MS in Baranya County was 37/100,000 (Pálffy,  1983).  In
Csongrád  County,  the  crude  prevalence  of  MS was  found to  be  62/100,000,  reported  by
Bencsik et al. in 2001 (Bencsik et al., 2001).     
I.3. Pathomechanism of MS
The etiology of MS is unknown. The damage of the central nervous system (CNS) is
caused by an inflammatory process, which leads to the impairment of the myelin coating of
the axons and thus axon degenerations. This demyelination process is influenced by genetic,
9environmental, infectious and other agents.
The  role  of  genetic  factors  in  MS susceptibility  was  confirmed  by several  cross-
sectional studies of patients with MS and their families, as well as by twin studies (Sadovnick
& Baird, 1988; Ebers et al., 1986). Studies of adoptive relatives, half-siblings and offsprings
of  conjugal  pairs  also  supported  these  data  (Ebers  et  al.,  1995;  Sadovnick  et  al.,  1996;
Robertson et al., 1997). In 1975, a relationship between MS and the major histocompatibility
complex  (MHC) was  confirmed (Jersild  et  al.,  1975).  Futhermore,  through  a  genomwide
linkage  study,  it  was  confirmed  that  the  HLA  DRB1*15:01  allele  is  linked  to  MS
susceptibility (GAMES Study, 2003). In subsequent years, several MHC- and other loci were
confirmed as  susceptibility factors  for  MS (ANZgene Consortium,  2009;  De Jager  et  al.,
2009, Hafler et al., 2007; Sawcer et al., 2011). Ebers et al. in 1995 showed that the family risk
is 300 times higher in monozygotic twins, and 20-40 times higher in biological first-degree
relatives  than  in  the  normal  population.  They  estimated  the  familial  prevalence  of  MS
between 5 and 10% (Ebers et al., 1995). Lately, numerous studies on the recurrence risk of
MS managed to define several associated loci, which can explain the heritability of MS, or to
estimate  the  potential  influence  of  environmental  factors.  According  to  the  data  of  the
International Multiple Sclerosis Genetics Consortium (IMSGC), over 100 associated genes
were confirmed (IMSGC et al., 2013). 
In  Hungary,  the  APOE  gene  and  the  tumor  necrosis  factor  alpha  gene-376
polymorphisms  were  examined  in  patients  with  the  primary  progressive  form of  MS by
Losonczi et al. (Losonczi et al., 2009; Losonczi et al., 2010). Their data confirmed that certain
alleles of APOE gene (ε2 and ε4) play a role in the development of MS, and the G allele of
the  TNF-alpha  gene-376  polymophism  may  be  one  of  the  factors  responsible  for  the
progression in primary progressive MS.      
The principal environmental factors are the viral infections, such as Epstein-Barr virus
(Handel et al., 2010), polio virus, HSV and rubeola. Besides these, smoking (Hawkes, 2007),
stress and the relative deficiency of vitamin D (Islam et al., 2007; Munger et al., 2004) are the
susceptibility factors of MS. 
The damage of the myelin, the oligodendrocytes and the axons are caused by immune-
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mediated processes involving both the innate and the adaptive immune system. (Koch et al.,
2013). The innate immune system plays a role both in the initiation and progression of MS,
and  also  modulates  the  adaptive  immune  system.  Due  to  antigene  presentation,  CD4+
lymphocytes and CD8+ lymphocytes are activated in the peripheral lymph tissues (Viglietta et
al., 2004). In people with MS, the pro-inflammatory lymphocytes, such as the Th1 and Th17
lymphocytes get activated and start to proliferate. (Lubetzki & Stankoff, 2014; Durelli et al.,
2009). These cells secrete pro-inflammatory cytokines and matrix metalloproteinases, which
disrupt  the  blood brain  barrier  (Obermeier  et  al.,  2013).  Through the  blood brain  barrier
damage, T and B cells, monocytes and macrophages migrate into the central nervous system.
A damaging inflammatory cascade starts up in the central nervous system involving the T and
B cells, monocytes, macrophages and microglial cells (Babbe et al., 2000). 
Futher studies demonstrated that free radicals and reactive oxygen species may cause
mitochondrial  damage,  and  the  iron  deposition  may  contribute  to  demyelination  and
oligodendrocytes damage. Nitrous oxide may also have an important role in these process
(Haider et al., 2011; Witte et al., 2014; Trapp & Stys, 2009). 
I.4. Natural history of MS
MS occurs in four clinical forms (Lublin & Reingold, 1996; Lublin et al., 2014). These
are  the  relapsing-remitting  (RRMS),  the  secondary  progressive  (SPMS),  the  primary
progressive (PPMS) and the progressive-relapsing (PRMS) clinical courses. The relapsing-
remitting form is the most common disease course. In this case, patients have relapses or
exacerbations, during which their neurological functions worsen. After each relapse, a partial
or complete recovery period takes place, which is called remission. 
SPMS occurs in people who earlier had a relapsing-remitting clinical form of MS. At
the first relapses, the disability level does not increase, but with time, the damage and the loss
of the axons become dominant. From this time on, the disease turns into its progressive phase,
either with or without relapses. 
Patients with the primary progressive clinical form are characterized by a continuous
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worsening of neurological function without relapses (Lassmann et al.,  2012). This disease
course differs from RRMS in several factors: the female-male ratio in PPMS is approximately
equal and the disease begins around ten years later than in the case of RRMS. The lesions of
the central nervous system are also different from those in the clinical form with relapses.
Furthermore, in case of the primary progressive clinical form, there are more lesions in the
spinal cord than in the brain, and the lesions contain fewer inflammatory cells than in patients
with RRMS. 
The  relapsing-progressive  clinical  form of  MS is  very rare.  It  is  characterized  by
worsening of the neurological function and relapses from the beginning of the disease. 
A relatively new term, the „clinically isolated syndrome” (CIS) (Miller et al., 2012),
describes the first episode of the neurologic symptoms that goes on at least for 24 hours and is
caused  by inflammation  and  demyelination  in  one  place  or  several  places  in  the  central
nervous system. In CIS, it is obligatory to follow up the patients by MRI. If CIS is combined
with MRI detected lesions, which are similar to MS lesions, patients belong to the high risk
for  MS  group.  By these  patients,  it  is  suggested  to  begin  the  treatment  with  a  disease-
modifying medication to delay the second relapse, which is the onset of MS (Comi et al.,
2009; Kappos et al., 2006; Comi et al., 2001; Jacobs et al., 2000). 
Benign MS is an obsolete term for patients having only mild disability for more than
15 years in their case history. The term is no longer used as it was shown that 45% of the
patients with „benign MS” have cognitive impairment, 49% of them have fatigue and 54% of
them have depression (Amato et. al., 2006). 
I.5. Symptoms of MS
If there is  evidence for at least two areas of CNS damage that occurred at different
times,  the  diagnosis  of  MS can  be  adjudged.  The  symptoms  and  signs  of  MS  are  very
diversified,  they  may  also  mimic  other  diseases.  Furthermore,  the  symptoms  of  two
individuals may be very different from each other. 
The most common symptoms are numbness or tingling of the face, the body or the
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extremities, weakness and vision problems. The latter is often the first symptom of MS, which
evaulates promptly and manifests as blurred or doubled vision, possibly poor contrast or color
vision,  and  often  pain  during  eye  movement.  The  other  frequent  symptoms  of  MS  are
dizziness, spasticity, bladder dysfunction or constipation caused by bowel problems. Walking
difficulty is also a characteristic symptom of people with MS caused by weakness, spasticity,
loss of balance or sensory deficit. Symptoms of cerebellar damage, such as ataxia or intention
tremor, are also typical for MS. 
The  above  mentioned  symptoms  can  be  examined  in  the  course  of  the  routine
neurological examinations, which we performed every three months in case of our patients at
the  Department  of  Neurology in  Szeged.  With physical  examination,  the  patients'  rate  of
disability can be determined by the neurologist.
The generally used score to define the level of disability of patients with MS is  the
Expanded Disability Status Scale (EDSS) score, which was developed by John F. Kurtzke
(Kurtzke, 1983). This is a scale from zero to ten points. The steps from 1.0 to 4.5 belong to
those patients who are fully ambulatory.  From 5.0 points disability impairs  daily activity,
therefore the patients need aid for walking. The highest score, EDSS 10.0 indicates death
caused by MS. 
However,  several  aspects  of  MS  are  not  detectable  by  EDSS.  These  aspects  are
fatigue, depression, pain, sexual dysfunction and cognitive dysfunction.
I.6. Fatigue
Fatigue,  which  can  be  described  as  a  lack  of  energy,  sense  of  exhaustion  or  an
abnormal feeling of trouble, fundamentally influences the patients' daily activity.  Fatigue is
found as an early symptom in 20% of the patients, while in chronic cases, its frequency can be
as  high as  80% (Lerdal  et  al.,  2003).  Fatigue  limits  the  personal  interactions  of  patients,
impairs their quality of life, and also hinders the patients in their jobs. This symptom is the
most crippling symptom of MS according to the majority of the patients. In certain cases,
fatigue is the only manifestation of an acute MS relapse (Flachenecker & Meissner, 2008).
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Three forms of fatigue were described: physical, cognitive and social fatigue (Bakshi, 2003;
Vucic et al., 2010). 
In case of physical fatigue, the patients need to rest to continue their activity, because
due to the function of the muscles, the patients' extremities transitionally paralyse, and a rest
is necessary for their proper function. It was proven that a conduction block stands in the
background of  this  phenomenon (Braley & Chervin,  2010).  Under  demyelination,  the Na
channels free up in the axons, and therefore, the conduction of the impulse gets slower. By
muscle  activity,  the  demyelinated  motor  nerves  warm  up,  which  increases  the  rate  of
impairment,  and induces conduction block. By the rest,  the temperature decreases,  so the
muscles can move again. 
The diagnosis of social and cognitive fatigue is not as obvious as physical fatigue.
Patients  with  cognitive  fatigue  are  not  able  to  concentrate  for  longer  times,  and  have
difficulties  with  counting  or  reading.  Patients  with  social  fatigue  may  get  isolated  from
people, since they cannot participate in a long conversation. 
To determine whether or not  a patient  has fatigue,  questionnaires are used widely.
Although questionnaires are  somewhat subjective,  they yield useful information about  the
patients' everyday life. The most frequently used questionnaires are the Fatigue Severity Scale
(FSS)  (Krupp  et  al.,  1989),  the  Fatigue  Impact  Scale  (FIS)  (Fisk  et  al.,  1994),  and  the
Modified  Fatigue  Impact  Scale  (MFIS)  (Achiron  et  al.,  2015).  While  the  FSS  is  one-
dimensional, measuring only physical fatigue, the FIS and MFIS assess all three aspects of
fatigue. The completed FIS questionnaire contains 40 statements, the MFIS is a 21-item scale,
each with a score ranging from 0 to 4 points, giving information on the last 4 weeks of the
patients. The Hungarian version of the FIS was validated in 2011 (Losonczi et al., 2011).
Based on its pathomechanism, primary or secondary fatigue are distinguished. Recent
studies confirmed that primary fatigue is a result of the malfunctioning immune system and of
the damage of central nervous system in MS. Proinflammatory cytokines, such as interferon-
gamma and TNF-alfa were proven to play a role in fatigue (Sharief & Hentges, 1991; Hirsch
et al., 1985). A study showed that the level of TNF-alfa and interferon-gamma is significantly
higher in fatigued patients with MS compared to patients without fatigue (Heesen et al., 2006;
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Flachenecker et al., 2004).  
The other possible cause of fatigue may be the endocrine disfunction. Several studies
examined the ACTH level in fatigued patients with MS (Gottschalk et al., 2005). The gained
results  were not  definitive,  but  it  was shown that  the corticosteroid therapy increases  the
patients' level of energy in the MS relapse. 
The third group of primary fatigue causes include axonal loss and altered cerebral
activation. A decreased glucose metabolism in the frontal cortex and basal ganglia of fatigued
patients was confirmed with positron emission tomography (PET) (Roelcke et al., 1997). The
reduction of N-acetylaspartate/creatine (NAA/Cr) ratios in several brain areas detected by
magnetic resonance spectroscopy (MRS) in patients with fatigue suggests axonal loss in the
brain, which may lead to fatigue (Tartaglia et al., 2004; Tellez et al., 2008). 
Frequent causes of secondary fatigue include sleep disorders, depression and several
medicaments used to treat MS. The most common sleep disorders among patients with MS
are:  restless  legs  syndrome,  periodic  limb  movement  disorder,  chronic  insomnia,  and
circadian rhythm disturbances (Kaynak et al., 2006; Kaminska et al., 2011;  Veauthier et al.,
2013; Veauthier & Paul, 2014). 
Drugs, which can cause fatigue, include antispasmodics, such as cyclobenzaprine and
benzodiazepines, as well as pain medications and anxiolytics. An immunosupressive therapy
with  interferon  beta  agents  can  also  cause  fatigue,  because  interferon  beta  therapy often
causes flu-like symptoms and fever (Plosker, 2011). 
Depression  can  be  a  symptom of  MS,  but,  on  the  other  hand,  it  can  also  cause
secondary fatigue (Patrick et al., 2009). Depression in MS is very common, major depression
occurs  in  15.7%  of  patients,  which  means  a  2.3  times  higher  risk  than  in  the  normal
population (Patten et al., 2003). It is suggested by several studies that only a small proportion
of patients with MS receive effective treatment for their depression. Depression can lead to
interruption of immunomodulatory therapy, to more severe fatigue and to the failure of the
health-related quality of life in case of patients with MS. (Sadovnick et al., 1996).
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I.7. Health-related quality of life 
According to the definition of World Health Organization (WHO), health is a state of
complete  physical,  mental,  and social  well-being,  not  merely the absence of disease.  The
measurement of the quality of life is used as an assessment of the well-being in a social,
emotional  and  physical  sense. The  health-related  quality  of  life  expresses  how  these
parameters change over time due to a disease or its treatment (Vickrey et al., 1995; Hadgkiss
et al., 2013). 
Over  the last  decades,  there was an expansion of  studies examining health-related
quality  of  life  in  patients  with  MS.  To  measure  this  factor,  questionnaires  are  the  most
adequate tools. Three types of questionnaires are used: general, specific and combined ones.
Combined  questionnaires  contain  general,  health-related,  as  well  as  disease-specific
questions. General questionnaires are used in population-based studies with large number of
cases, while specific questionnaires are the most competent to analyze patients with a certain
disorder.  With the use of a  combined questionnaire,  the quality of life  of patients having
different disorders with the healthy population can be compared. 
The most  frequently utilized questionnaire  in MS to estimate quality of life is  the
Multiple  Sclerosis  Quality  of  Life  Questionnaire  (MSQoL-54),  which  is  a  combined
questionnaire.  This  was  developed for  English-speaking  patients,  and  contains  general
questions regarding the quality of life (Short Form-36) and 18 specific questions for patients
with MS (Vickrey et  al.,  1995). The total of 54 questions can be divided into 14 groups:
Physical health, Role limitations due to physical problems, Role limitations due to emotional
problems, Pain, Emotional well-being, Energy, Health perceptions, Social function, Cognitive
function,  Health distress,  Overall  quality of life,  Sexual function,  Satisfaction with sexual
function and Change in health. 
The MSQoL-54 was validated in Hungary in 2008  (Füvesi et  al.,  2008).  The first
multicentre survey with this questionnaire was performed in Hungary in 2010 (Füvesi et al.,
2010). The questionnaire was given to more than 400 patients. It was confirmed that 62.1% of
the patients had at least one comorbid disease besides MS. Furthermore, Füvesi et al. proved
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that the quality of life of patients with depression was significantly lower than that of the
patients without depression.
I.8. Diagnostic criteria for MS
MS is characterized by the signs of multiple neurological dysfunctions followed by
remission and increasing functional disability. MS cannot be diagnosed with a simple test.
The diagnosis  is based on the neurological examination of the patient, laboratory tests and
MRI data. These results, together with anamnestical data, allow us to prove the dissemination
of neurological symptoms in space and time. 
Earlier epidemiological studies used the Poser Committee Criteria for the diagnosis
(Poser et al., 1983). The diagnostic criteria by Poser are based on the number of relapses and
several additional tests, such as the measurement of visual evoked potential (VEP) and the
analysis of the cerebrospinal fluid for increased number of oligoclonal bands and/or elevated
IgG level. On the basis of the results, four categories can be distinguished: clinically definite
MS,  laboratory-supported  definite  MS,  clinically  probable  MS  and  laboratory-supported
probable MS. 
For  the  diagnosis  of  MS,  the  McDonald  criteria  and  their  new  versions  were
introduced in 2001, 2005 and 2010 (McDonald et al., 2001; Polman et al., 2005; Polman et
al., 2011). Using these new criteria, which are based on MRI data, the patients can receive a
diagnosis of MS or possible MS. As compared to the Poser criteria, the McDonald criteria
enables  the  diagnosis  of  MS  in  a  much  shorter  time  after  the  recognition  of  the  first
symptoms. The period between the first relapse and the diagnosis of definitive MS became
notably shorter.
I.9. Treatment of MS
A curative therapy for MS is not yet available, however, to alleviate the symptoms of
MS, three types of medications exist. The first type modifies the course of the disease, the
17
second treats relapses, and the third manages the symptoms of MS. 
With the use of disease-modifying agents, the disease activity can be reduced. The
latest  available first-line disease-modifying drugs are the interferon beta-1a 30  µg weekly
intarmuscular  injection,  the  interferon  beta-1a  44  µg  subcutaneous  injection  three  times
weekly, the interferon beta-1b 250 µg subcutaneous every other day, the glatiramer acetate 20
mg daily subcutaneous injection, the dimethyl fumarate 240 mg twice daily oral medicament
and the teriflunomid 14 mg daily oral drug (Jacobs et al., 1996; PRISMS Study Group, 1998;
The IFNB Multiple Sclerosis Study Group, 1993; Johnson et al., 1995; Gold et al., 2012; Fox
et  al.,  2012;  O'Connor  et  al.,  2011).  All  first-line  immunomodulatory  agents  reduce  the
activity of MS, and slow down the progression of disability at around a similar rate, however,
the mechanism of their action and their side effects are different. 
In fact, the major difference between interferon beta agents and glatiramer acetate is
that interferon beta therapy can cause flu-like symptoms, inflammation next to the injection-
site, hepatic abnormalities and depression while these side effects are not typical in glatiramer
acetate therapy (Plosker, 2011). 
I.10. Glatiramer acetate
Glatiramer acetate (GA), known as copolymer 1, is a mixture of synthetic polypeptides
composed of four amino acids, was approved for use in Hungary in 1999. This synthetic
molecule is very similar to the myelin basic protein. Since it was very effective in preventing
the experimental autoimmune encephalomyelitis, the animal model of MS, it was later tested
in different clinical studies. The mechanism of its effect is complex. Glatiramer acetate binds
strongly to major histocompatibility complex molecules and competes with various (myelin)
antigens  for  their  presentation  to  T cells  (Fridkis-Hareli  et  al.,  1994).  Glatiramer  acetate
therapy not only changes the frequency and the pattern of cytokine secretion in vivo, but also
modulates the effector function of GA-specific CD4+ and CD8+ T cells (Karandikar et al.,
2002). Glatiramer acetate affects the properties of antigen-presenting cells, such as monocytes
and dendritic cells. It promotes the differentiation of T cells to Th2 and T-regulatory cells,
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which then migrate to the brain (Duda et al., 2000; Vieira et al., 2003). This leads to in situ
bystander suppression of the inflammatory process in the brain. Furthermore, in the brain,
these cells release neurotrophic factors, such as the brain-derived neurotrophic factor (BDNF)
and anti-inflammatory T helper 2-like cytokines (Graber et al., 2010). 
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II. Aims
The aims of our studies were to:
1. determine  the  age-  and  sex-specific  crude  and  standardized  prevalence  of  MS
according to  the McDonald criteria  in  Csongrád County on the prevalence day (1
January 2013);
2. determine the prevalence of familial MS in Hungary;
3. determine  the  prevalence  of  fatigue  and  depression  in  glatiramer  acetate-treated
patients in Hungary;
4. compare the health related quality of life in fatigued and non-fatigued patients;
5. analyze  the  correlation  of  fatigue,  depression,  clinical  disability  and  the  disease
duration with the health-related quality of life in case of patients with MS.
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III. Patients and methods
III.1. Prevalence of MS in Csongrád County
Csongrád County is  located  in  the  south-eastern  region of  Hungary.  Its  climate  is
humid continental.  The Hungarian Central Statistical Office performed the latest census in
2011. According to the available data, at that time, 421,827 people lived in Csongrád County:
199,388 males and 222,439 females. Hungarians were accounting for 85% of the population
(source: ksh.hu).
At  the  Department  of  Neurology,  University  of  Szeged,  an  MS  outpatient  unit
functions  for  the  inhabitants  of  Csongrád  County.  Since  1996,  this  outpatient  unit  has
maintained an MS register containing regularly updated patient records. From the region of
the Southern Great Plain, all suspected MS cases are investigated at the MS Centre of the
University of Szeged to confirm the diagnosis. Until 2001, the diagnosis was established by
neurology specialists  according to the Poser criteria. Since the introduction of the McDonald
criteria, the neuroradiologist is responsible for the medical record. 
Patients  are  examined every 3  months  for  their  neurological  status,  the  Expanded
Disability Status Scale (EDSS) score and the clinical form of MS are also checked. For the
diagnosis of MS, brain MRI and, if necessary, spinal cord and optic nerve MRI examinations
are required.  In  our accredited laboratory (ISO 9002),  we analyze  the cerebrospinal  fluid
samples. We perform laser nephelometry for the quantitative analysis of proteins, isoelectric
focusing and IgG immunoblotting to detect oligoclonal bands. According to the McDonald
criteria, in case of patients with clinically isolated syndrome (CIS), we perform control MRI
examinations 3 and 6 months after the appearance of the first symptom. If we do not detect
new lesions, we control MRI examinations every 3 months. Patients with clinically definitive
MS undergo MRI examination yearly. Patients who receive with disease modifying therapy
undergo MRI examinations yearly in the first two years of the treatment, and in case of a new
relapse.  In  case  of  a  relapse,  we  have  an  unscheduled  visit,  at  which  we  record  the
neurological status and the EDSS score of the patient. 
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Patients,  who had earlier  been presumed to have  MS, but  whose  diagnosis  is  not
relevant  after  the  revision  of  the  hospital  archives,  are  excluded  by  three  independent
neurology specialists. In case of a relevant diagnosis, the patient's medical history is recorded
in  the  MS  registry.  The  medical  history  contains  the  patient's  relapse  rate,  EDSS score,
paraclinical examinations data, the clinical form and the date of onset of MS. Deaths due to
MS are identified from the pathological records and the certificates of death. 
In our prevalence study, we included the patients with clinically isolated and clinically
definitive MS living in Csongrád County on the prevalence day. The patients with relapsing-
remitting  clinical  form  had  to  be  in  a  stable  neurological  state  and  in  remission  at  the
prevalence day. The duration of the disease was counted from the onset of the first symptom. 
We  documented  the  female/male  ratio,  the  proportion  of  each  clinical  form,  the
number of new patients and the number of patients who moved away from the county during
the study period. We also monitored the different disease-modifying treatments (DMTs). 
Age-  and  sex-adjusted  prevalence  of  MS was  calculated  by the  direct  method  of
standardization using the European Standard Population as reference. The study was approved
by the Human Investigation Review Board of the University of Szeged (approval number
3267) in accordance with the Helsinki Declaration. 
III.2. Familial aggregation of MS in Hungary
In 2004, with the contribution of five MS centers in Hungary, we collected MS cases
implying familial aggregation. Altogether, 1500 patients were treated in the MS centres. The
distribution of patients between the five centres is shown in Table 1. The patients participating
in  the  study  were  diagnosed  by  the  McDonald  criteria.  The  patients  showed  relapsing-
remitting, secondary progressive and benign clinical forms. The distribution of the patients
and the families with MS among the five MS centres is shown the Table 1.
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Number of MS families
MS centres Number of patients Cases Families
Szeged 700 14 6
Debrecen 200 4 2
Budapest 1. 150 6 3
Budapest 2. 300 7 3
Kecskemét 150 2 1
Table 1. Number of examined patients with MS in the five MS centres in Hungary
III.3. Prevalence of fatigue and its effect on HRQoL in MS
III.3.1. Participants and measures
For the quality of life study, data of 428 patients with MS from 19 Hungarian multiple
sclerosis centres were collected. The patients had the relapsing-remitting clinical form, and
were treated with glatiramer acetate. The relevant socio-demographic and disease-related data
were  collected  from  the  multiple  sclerosis  registers  at  the  centres.  The  diagnosis  was
confirmed according to the 2005 modification of the McDonald criteria (McDonald et al.,
2001;  Polman et  al.,  2005).  The distribution  of  the patients  among the multiple  sclerosis
centres is shown in Table 2. 
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Centres No. of patients
1. Dept. of Neurol., F. Jahn Hosp. of South-Pest, Budapest, Hungary 48
2. Dept. of Neurol., Hungarian Military Hosp., Budapest, Hungary 3
3. Dept. of Neurol., St. István Hosp., Budapest, Hungary 4
4. Dept. of Neurol., Univ. of Debrecen, Debrecen, Hungary 25
5. Dept. of Neurol., Gy. Kenézy Hosp., Debrecen, Hungary 18
6. Dept. of Neurol., A. Petz County Hosp., Győr, Hungary 11
7. Dept. of Neurol., M. Kaposi Hosp., Kaposvár, Hungary 24
8. Dept. of Neurol., Bács-Kiskun County Hosp., Kecskemét, Hungary 25
9. Dept. of Neurol., BAZ County Hosp., Miskolc, Hungary 21
10. Dept. of Neurol., A. Jósa Hosp., Nyíregyháza, Hungary 19
11. Dept. of Neurol., Univ. of Pécs Med. School, Pécs, Hungary 40
12. Dept. of Neurol., Univ. of Szeged, Szeged, Hungary 74
13. Dept. of Neurol., Tolna County Hosp., Szekszárd, Hungary 9
14. Dept. of Neurol., St. György Hosp., Székesfehérvár, Hungary 16
15. Dept. of Neurol., G. Hetényi County Hosp., Szolnok, Hungary 18
16. Dept. of Neurol., L. Markusovszky Hosp., Szombathely, Hungary 22
17. Dept. of Neurol., K. Vaszary Hosp., Esztergom, Hungary 6
18. Dept. of Neurol., Uzsoki St. Hosp., Budapest, Hungary 38
19. Dept. of Neurol., Zs. Bajcsy Hosp., Budapest, Hungary 7
 
Table 2. Hungarian multiple sclerosis centres participating in the study
The inclusion criteria of the study were the following: the patients had a relapsing-
remitting form of MS, the glatiramer acetate treatment period was longer than one year, the
patients were in remission for at least 30 days, the patients were off steroid therapy for more
than 30 days, the patients had an EDSS score between zero and 5.5, and the patients were
more than 18 years old. 
The patients completed the Hungarian versions of the MSQoL-54, the FIS and the
Beck  Depression  Inventory (BDI)  questionnaires  for  the  assessment  of  QoL,  fatigue  and
depression.  The BDI provides 21 grouped assertions on how the patient has been feeling
during the week before. Each question has a set of at least four possible answers. With a total
score above 21 points, the patient is regarded to have depression (Beck et al., 1961).
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III.3.2. Ethics
The personal data of the patients were subject to strict confidentiality. All participants
received appropriate information about the study both in written form and orally. They gave
their written consent to statistical evaluation of their answers. The study was approved by the
Science and Research-ethics Committee of the Medical Science Council in Hungary (3462-
0/2010-1018EKU (197/PI/10)) and was in full accord with the Declaration of Helsinki. The
same, ethically approved information sheet and consent form were given to the participating
patients at each centre.
III.3.3. Statistical analysis 
Statistical analysis was carried out with the Statistical  Package for Social  Sciences
(SPSS 19.0, SPSS Inc., http://www.spss.com); the level of significance was predefined at p <
0.05.  For  determination  of  the  prevalence  of  fatigue  and  depression,  we  used  frequency
analysis. Correlation coefficients and partial correlation coefficients were applied to assess the
influence of the EDSS score, depression, fatigue and the disease duration on the quality of
life. The predictors of the quality of life were determined by linear regression. The data on the
fatigued and the non-fatigued patients were compared with the independent samples t-test.
Our study is an exploratory pilot study, therefore no correction for multiple comparisons was
made. 
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IV. Results
IV.1. Prevalence of MS in Csongrád County
In Csongrád County,  1999, our MS register listed 249 patients.  Between 1999 and
2013, the number of new MS cases was 259. In that fourteen years, 86 patients died, and 30
moved  away  from  the  county.  Thirteen  patients  were  misdiagnosed,  in  their  case,  the
longitudinal follow-up eventually ruled out MS (seven patients had neuromyelitis optica, 6
patients had autoimmunity-related vasculitis).
According to data of the Hungarian Central Statistical Office, in 2013, 421,827 people
lived in Csongrád County (199,388 males, and 222,439 females). On the day of prevalence
determination, January 1, 2013, 379 patients were registered in our MS register. On the basis
of these data, the crude prevalence of MS was 89.8/100,000 (46.6/100,000 among males and
128.6/100,000 among females). The standardized prevalence was 83.7/100,000 for the overall
MS population (42.3/100,000 for men and 122.6/100,000 for women).  The age-  and sex-
adjusted prevalence data are detailed in Table 3. The female/male ratio was 3.08 in the MS
population and 1.12 in the overall county population.
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Men Women Total
Age  groups
(years)
Cases Prevalence Cases Prevalence Cases Prevalence
15> 0 0.0 0 0.0 0 0.0
15-19 0 0.0 2 16.4 2 8.0
20-24 3 20.4 9 62.8 12 41.4
25-29 14 92.1 22 147.0 36 119.3
30-34 9 50.4 24 141.3 33 94.7
35-39 10 60.4 38 238.0 48 147.6
40-44 15 103.6 37 259.5 52 180.9
45-49 5 41.5 27 214.8 32 130.0
50-54 9 68.3 41 276.5 50 178.6
55-59 14 97.4 32 187.4 46 146.3
60-64 9 76.5 29 193.0 38 141.9
65-69 2 21.0 15 114.8 17 75.2
70< 3 17.0 10 0.0 13 25.7
Crude 93 46.6* 286 128.6* 379 89.8*
Age-sex-
adjusted
42.3# 122.6# 83.7#
* Crude prevalence per 100,000 population.
#  Standardized  prevalence  per  100,000  population  (The  European  Standard  was  used  as
reference population in the direct standardization).
Table 3. Sex- and age specigic prevalence of MS in Csongrád County on 1 January 2013
The distribution of the clinical forms was the following: clinically isolated syndrome
(CIS): 11% (n=44), relapsing-remitting form: 69% (n=260), secondary progressive form: 14%
(n=52) and primary progressive form: 6% (n=23).
The demographic data of the patients in the different clinical forms of MS are shown in Table
4.
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CIS RRMS SPMS PPMS
Mean duration of
MS (years)
4.7 ± 4.0
(range: 0-55) 
12.9 ± 9.1
(range: 0-55)
21.7 ± 9.4
(range: 4-47)
8.5 ± 5.9 
(range: 1-23)
Mean  age  at  the
onset  of  MS
(years)
31.4 ± 9.6
(range: 19-61)
31.7 ± 9.1
(range: 5-59)
35.4 ± 12.0
(range: 13-64)
47.3 ± 8.8
(range: 20-61)
Table 4. Demographic data of patients in the different clinical forms of MS 
The mean EDSS score in the group of patients with clinically isolated syndrome was
0.4 ± 0.6. In the relapsing-remitting group, 91.9% of the patients (n=239) had EDSS scores in
the range between 0 and 4. The EDSS of 8.1% of the patients in this group (n= 21) was
between 4.0 and 6.5. In the secondary progressive group, 53.8% (n=28) of the patients had
EDSS scores between 4.0 and 6.5, and 46.2% of SPMS patients (n=24) had scores higher than
7. In the primary progressive group, 26.1% of patients (n=6) had EDSS scores between 2 and
3.5, 13% (n=3) had a score of 4, 34.8% (n=8) had scores between 4.5 and 6.5, 26.1% (n=6)
had scores of seven or higher. 
We  confirmed  that  73.1%  of  the  MS  population  received  some  sort  of  disease-
modifying therapies (DMTs). Those who received any kind of DMTs in the first 5 years after
the established diagnosis had a mean EDSS score of 1.1 ± 1.0 (range: 0-3.5), and those who
received it between 5 and 10 years after the diagnosis had a mean EDSS score of 1.8 ± 1.3
(range:  0-5.5).  The mean EDSS score among the patients,  who spent  10 years  or  longer
without disease-modifying therapy after the MS diagnosis was 2.1 ± 1.1 (range: 0-4).
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IV.2. Familial aggregation of MS in Hungary
In 2006, with the collaboration of five Hungarian MS centres, we found 33 patients
from 15 families among 1500 patients. This number includes a monozygotic twin pair, of
which one patient showed the secondary progressive form (EDSS score of 8) of MS, and the
other had benign MS. We also found a dizygotic twin pair, whose father had died of MS 20
years  before.  In  another  family,  MS  affected  three  generations  (mother,  son  and
granddaughter). In the remaining cases, the first-degree relatives affected by MS were the
followings: mother-daughter, father-son, sister-sister, brother-sister and three sisters. 
Based on our data, which represented 25% of all MS patients in Hungary, we estimated a 2%
familial rate of MS.
IV.3. Prevalence of fatigue and its effect on HRQoL in MS
IV.3.1. Demographic and clinical measures
The demographic data of the patients with relapsing-remitting form of MS were the
followings: the average age of the patients was 43.6 years (95% confidence interval  [CI]
42.6–44.6), the male to female ratio was 1:2.8, the mean disease duration of MS from the date
of diagnosis was 11.2 years (95% CI 10.6–11.9),  the mean duration of glatiramer acetate
treatment was 6.6 years (95% CI 6.2–6.9) and the median EDSS score was 2.0 (95% CI 2.2–
2.5).  The percentage  of  the  married  respondents  was 60.7%,  and 83.8% had one  or  two
children. Around 66% had participated successfully in secondary education, and about 33%
had done so in higher-level education. 
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IV.3.2. Main outcome measures
In our multicentre study, from 428 patients with relapsing-remitting MS treated with
glatiramer  acetate,  402  and  381  patients  answered  all  questions  in  the  FIS  and  BDI
questionnaires, respectively. In case of the MSQoL-54 questionnaire, in each question group,
an average of 60 of the questionnaires could not be evaluated due to missing data. In the
question groups relating to the sexual function and the satisfaction with the sexual function
this rate was higher, with more than 80 cases.
Based on the data used the FIS questionnaire, the prevalence of fatigue was 62.4%
(251 of 402 patients). Using the BDI, we confirmed the prevalence of depression in 13.4% of
the  patients  (51  of  381 patients).  Both  questionnaires  were  filled  out  completely by 278
patients,  among  whom no  one  had  depression  without  fatigue.  However,  35  of  the  168
fatigued patients (20.8%) had depression as well. We compared the health-related quality of
life of patients with fatigue to that of the patients without fatigue and found that non-fatigued
patients assessed their  health-related quality of  life  significantly higher  than patients  with
fatigue in all question groups of the MSQoL-54 questionnaire (Table 5). 
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t-test for equality of means
N Mean
St.
dev.
St.
err.
mean
t df
Sig.
(2-
tailed)
Mean
diff.
St.
error
diff.
95% CI of the
diff.
Lower Upper
„Overall, how 
would you rate 
your own 
quality of life?”
NF 131 7.69 1.608 0.14 12.386 323 0.001 2.326 0.188 1.957 2.696
F 194 5.36 1.695 0.122 12.514 288.797 0.001 2.326 0.186 1.96 2.692
„Which best 
describes how 
you feel about 
your life as a 
whole?”
NF 131 5.39 1.113 0.097 10.513 325 0.001 1.379 0.131 1.121 1.637
F 196 4.01 1.194 0.085 10.661 291.742 0.001 1.379 0.129 1.124 1.634
Overall quality 
of life scale%
NF 131 75.013 14.852 1.298 13.144 325 0.001 23.014 1.751 19.57 26.459
F 196 51.998 15.943 1.139 13.331 291.92 0.001 23.014 1.727 19.617 26.412
General health 
scale%
NF 131 65.473 20.318 1.775 15.132 325 0.001 31.441 2.078 27.353 35.528
F 196 34.032 17.021 1.216 14.613 244.674 0.001 31.441 2.152 27.203 35.679
Cognitive 
function scale%
NF 130 85.692 17.239 1.512 11.423 323 0.001 26.923 2.357 22.286 31.56
F 195 58.769 22.888 1.639 12.074 318.167 0.001 26.923 2.302 22.536 31.31
Sexual function 
scale%
NF 128 88.997 16.367 1.447 8.192 311 0.001 24.973 3.049 18.975 30.972
F 185 64.024 31.68 2.329 9.108 290.671 0.001 24.973 2.742 19.577 30.37
Bodily pain 
scale%
NF 131 82.924 21.171 1.85 12.938 323 0.001 32.913 2.544 27.908 37.918
F 194 50.01 23.347 1.676 13.185 296.503 0.001 32.913 2.496 28.001 37.826
Table 5. Health-related quality of life of patients with or without fatigue (NF=no fatigue,
F=fatigue)
In our study, we examined the correlation of the EDSS score, depression, the three
dimensions  of  fatigue  and  the  disease  duration  with  the  health-related  quality  of  life,  as
examined with the MSQoL-54, by correlation analysis. Depression and the three dimensions
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of fatigue influenced all the subscales of the MSQoL-54 questions significantly negatively.
The EDSS score correlated significantly negatively with all aspects of the MSQoL-54, except
for the cognitive function scale. The disease duration had a significant negative correlation
with the quality of life, with the exception of the mental health, the cognitive function and the
satisfaction with the sexual function (data can be seen in Table 6). 
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EDSS
Cognitive
fatigue
Physical
fatigue
Social
fatigue
Depression
Duration of
disease
Physical Functioning 
Scale
r -0.541 -0.455 -0.707 -0.651 -0.423 -0.201
p 0.0001 0.0001 0.0001 0.0001 0.0001 0.0001
Role-Physical Scale r -0.422 -0.516 -0.655 -0.66 -0.452 -0.209p 0.0001 0.0001 0.0001 0.0001 0.0001 0.0001
Role-Emotional Scale r -0.241 -0.581 -0.578 -0.643 -0.523 -0.153p 0.0001 0.0001 0.0001 0.0001 0.0001 0.003
Bodily Pain Scale r -0.315 -0.567 -0.66 -0.655 -0.478 -0.138p 0.0001 0.0001 0.0001 0.0001 0.0001 0.008
Pain Scale (Vickrey) r -0.304 -0.581 -0.666 -0.674 -0.526 -0.145p 0.0001 0.0001 0.0001 0.0001 0.0001 0.005
Mental Health Scale r -0.181 -0.556 -0.569 -0.649 -0.716 -0.047p 0.0001 0.0001 0.0001 0.0001 0.0001 0.367
Vitality Scale r -0.328 -0.578 -0.723 -0.721 -0.591 -0.125*p 0.0001 0.0001 0.0001 0.0001 0.0001 0.016
Energy Scale (Vickrey) r -0.294 -0.577 -0.695 -0.705 -0.591 -0.134p 0.0001 0.0001 0.0001 0.0001 0.0001 0.01
General Health Scale r -0.358 -0.59 -0.698 -0.712 -0.563 -0.135p 0.0001 0.0001 0.0001 0.0001 0.0001 0.009
Social Functioning 
Scale
r -0.272 -0.57 -0.643 -0.705 -0.58 -0.11*
p 0.0001 0.0001 0.0001 0.0001 0.0001 0.033
Social Function Scale 
(Vickrey)
r -0.352 -0.605 -0.685 -0.739 -0.588 -0.151
p 0.0001 0.0001 0.0001 0.0001 0.0001 0.003
Cognitive Function 
Scale
r -0.084 -0.764 -0.528 -0.648 -0.603 -0.057*
p 0.106 0.0001 0.0001 0.0001 0.0001 0.276
Health Distress Scale r -0.292 -0.56 -0.649 -0.701 -0.617 -0.1*p 0.0001 0.0001 0.0001 0.0001 0.0001 0.053
Overall Quality of Life 
Scale
r -0.369 -0.545 -0.617 -0.675 -0.674 -0.133
p 0.0001 0.0001 0.0001 0.0001 0.0001 0.01
Sexual Function Scale r -0.224 -0.442 -0.517 -0.549 -0.486 -0.122*p 0.0001 0.0001 0.0001 0.0001 0.0001 0.022
Reported Health 
Transition Scale
r -0.262 -0.273 -0.412 -0.387 -0.317 -0.143
p 0.0001 0.0001 0.0001 0.0001 0.0001 0.006
Satisfaction with 
Sexual Function Scale
r -0.211 -0.406 -0.426 -0.471 -0.525 -0.097*
p 0.0001 0.0001 0.0001 0.0001 0.0001 0.071
Correlation is significant at the 0.01 level (2-tailed).
*Correlation is significant at the 0.05 level (2-tailed).
Table 6. Correlation of the level of disability, fatigue, depression and the duration of MS with
HRQoL
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By regression analysis, we confirmed that the overall quality of life was significantly
predicted by the EDSS score, depression and social fatigue (Table 7). By examination of the
patients separately on the basis of the presence of depression, we founded that in patients with
depression, social fatigue was the only factor that predicted the quality of life (Table 8). 
Coefficientsa
Unstandardized coefficients Standardized
coefficients
B Std. error Beta t Sig.
(Constant) 18.184 0.306 59.46 0.0001
EDSS -0.394 0.108 -0.155 -3.654 0.0001
Cognitive fatigue 0.057 0.029 0.152 1.947 0.052
Physical fatigue 0.032 0.033 0.094 0.996 0.320
Social fatigue -0.148 0.023 -0.785 -6.329 0.0001
Depression -1.742 0.478 -0.152 -3.643 0.0001
a Dependent variable: overall quality of life scale (N=349, R2=0.519)
Table 7. Predictors of the overall quality of life scale by linear regression
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Coefficientsa
Unstandardized
coefficients
Standardized
coefficients
B Std.
error
Beta t Sig.
No depression (Constant) 18.287 0.312 58.698 0.0001
EDSS -0.436 0.114 -0.186 -3.843 0.0001
Cognitive fatigue 0.058 0.031 0.157 1.875 0.062
Physical fatigue 0.023 0.034 0.069 0.661 0.509
Social fatigue -0.143 0.025 -0.768 -5.780 0.0001
Depression (Constant) 14.996 2.238 6.702 0.0001
EDSS -0.102 0.384 -0.046 -0.264 0.793
Cognitive fatigue 0.05 0.094 0.133 0.529 0.600
Physical fatigue 0.115 0.116 0.275 0.998 0.325
Social fatigue -0.177 0.081 -0.707 -2.200 0.034
a Dependent  variable:  overall  quality  of  life  scale  (N=305  and  44,  R2=0.448  and  0.170,
respectively)
Table  8. Predictors  of  the  overall  quality  of  life  scale  among  patients  without  or  with
depression by linear regression
At question 54 of the MSQoL-54, the patients evaluate their quality of life verbally
(Terrible (1) - Unhappy (2) - Mostly dissatisfied (3) – Mixed (about equally satisfied and
dissatisfied) (4) - Mostly satisfied (5) - Pleased (6) - Delighted (7)). By regression analysis,
we confirmed that the verbal characterization of the quality of life was predicted by the EDSS
score, depression, social and cognitive fatigue (R2=0.389, p<0.05). 
In case of the cognitive and the sexual quality of life, we found significant effects of
depression and cognitive fatigue (Tables 9, 10).
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Coefficientsa
Unstandardized
coefficients
Standardized
coefficients
B Std. error Beta t Sig.
(Constant) 85.468 2.060 41.499 0.0001
Depression -10.716 3.389 -0.142 -3.162 0.002
EDSS 1.344 0.744 0.082 1.806 0.072
Cognitive fatigue -27.332 2.988 -0.55 -9.147 0.0001
Physical fatigue -2.642 3.693 -0.051 -0.715 0.475
Social fatigue -6.473 3.891 -0.13 -1.663 0.097
aDependent variable cognitive function scale % (N=276, R2=0.527)
Table 9. Predictors of the cognitive quality of life by linear regression
Coefficientsa
Unstandardized
coefficients
Standardized
coefficients
B Std. error Beta t Sig.
(Constant) 91.62 3.077 29.774 0.0001
Depression -16.605 5.130 -0.182 -3.237 0.001
EDSS -1.705 1.121 -0.086 -1.521 0.129
Cognitive fatigue -14.892 4.468 -0.249 -3.333 0.001
Physical fatigue 0.511 5.503 0.008 0.093 0.926
Social fatigue -11.049 5.799 -0.185 -1.905 0.058
a Dependent variable: sexual function scale % (N=271, R2=0.273 )
Table 10. Predictors of the sexual quality of life by linear regression
36
V. Discussion
The  aim  of  an  epidemiological  study  on  the  prevalence  of  a  disease  is  to  give
comparable, standardized data from a certain region. The differences in the methodology, the
ethnic origins, the geographical areas and the age distributions in the different study groups
can  cause  discrepancies.  To  solve  this  problem,  sex-  and  age  adjustment  for  a  standard
population has to be used (Bauer, 1987).
In  1999,  Bencsik  et  al.  conducted  an  epidemiological  study  of  MS  in  Csongrád
County, which revealed a crude prevalence of 62/100,000 (Bencsik et al. 2001). This study
was based on the diagnostic criteria by Poser (Poser et al., 1983). The novel diagnostic criteria
by  McDonald  and  its  revisions  by  Polman  were  introduced  in  2001,  2005  and  2011
(McDonald et al., 2001, Polman et al., 2005, 2011). In our study, we examined the prevalence
of  MS diagnosed by these novel  criteria.  The crude prevalence  in  Csongrád County was
89.8/100 000, the standardized prevalence of MS was 83.7/100,000.                  
      Our results are in line with the data of other prevalence studies based on the McDonald
diagnostic criteria. In these studies, data were adjusted to the European standard population.
The standardized prevalence of MS was 203.4/100,000 in UK, in 2010; 74/100,000 in Osana,
Spain in 2008; 96/100,000 in Verona,  Italy,  in 2001 and 94.7/100,000 in France,  in 2004
(Mackenzie et al., 2014; Otero-Romero et al., 2013; Gajofatto et al., 2013; Fromont et al.,
2010). 
In Scandinavia, several prevalence studies were conducted. These studies included all
probable and possible MS cases according to the diagnostical criteria of Poser, and used the
European population as a reference. In Oppland County, Norway, the age-adjusted prevalence
of  MS  was  185.6/100,000  in  2002;  in  Vest-Agder  County,  Norway,  in  2007  it  was
186/100,000 (Risberg et al., 2011; Vatne et al., 2011). The latest prevalence study in Norway
was performed in 2013. The crude prevalence, based on the Norwegian Patient Registry, was
208/ 100,000 (Grytten et al., 2015). 
In 1990, Sundström et al. performed a prevalence study, in which the patients with
probable MS diagnosis were excluded. According to this study, the age-adjusted prevalence to
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the  European  standard  population  in  Västerbotten  County,  Sweden  was  126/100,000
(Sundström et al., 2001). The prevalence increased over time. On the 31st of December 2010,
it was 215/100,000 (Svenningsson et al., 2015).  Our prevalence results are lower than those
gained from the northern areas of Europe. This finding is in line with the known geographical
distribution of MS. 
An epidemiological study using the Poser criteria was performed in Belgrad in 1996,
and  the  prevalence  was  found  to  be  41.5/100,000  adjusted  to  the  world  population
(Pekmezovic et al., 2001). 
In 1999, a prevalence study, which was conducted in Croatia and Slovenia, using the
criteria of Poser and the European population as standard, found that age-adjusted prevalence
of  MS was 156.1/100,000 (Peterlin  et  al.,  2006).  This  value  is  almost  the  double  of  the
prevalence value found in our study. 
In western Hercegovina in 2003, the prevalence of MS based on the McDonald criteria
was 26.9/100,000. The European population was used as the standard population (Klupka-
Sarić et al., 2007). The prevalence value found in our study is higher than this, which may be
a result of the ten years that have passed since that time. 
Prevalence data from the Republic of Moldova were submitted this year. According to
these data, the standardized prevalence is 20.2/100,000. The patients with MS were diagnosed
by the McDonald criteria (Marcoci et al, 2016).  
The ratio of males to females was 1:2.75 in the MS population of Csongrád County,
reported by Bencsik et al. in 2001. This ratio was 1:1.09 in the whole population of the county
(Bencsik et al., 2001). In our study, we found the male:female ratio in the MS population to be
1:3.08, and 1:1.12 in the population of the whole county. These findings are in line with the
literature data, which suggests that MS is more frequent among women, and this difference
between the genders shows an increasing tendency (Orton et al., 2006). 
We examined the proportion of patients with different clinical forms. 68.6% of the
patients with MS showed the relapsing-remitting clinical form. Disease-modifying therapies
have been applied in Hungary since 1996. 73.1% of the patients with the relapsing-remitting
form of MS are treated with one of these drugs. Our study revealed that 91.9% of the patients
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with relapsing-remitting form have either no or only mild symptoms. The average disease
duration in the group of patients with RRMS was 12.9 years, which is four years longer than it
was in 1999, found by an earlier prevalence study in Csongrád County (Bencsik et al., 2001).
This  indicates  that  the  progression  of  MS  became  slower,  which  delays  the  shift  to  the
secondary progressive form. Due to the disease-modifying therapies, the patients with MS
stay in good physical condition for a longer time. 
Our findings were supported by an epidemiological study performed in Poland. This
study showed  that  in  2004,  40% of  the  patients  with  MS were  in  the  severe  secondary
progressive form, and after the introduction of disease-modifying treatments, in 2010, this
value decreased to 16% (Kulakowska et al., 2010; Obiŉska et al., 2004). 
We found that the percentage of the primary progressive form of MS is lower (6.1%)
than it was reported previously (11%) by Bencsik et al. in 2001. This reduction may be caused
by the death of the older patients with a severe state. This change of the patients' proportion
between the different stages of the disability is significant. While in 2001 more than 80% of
patients with primary progressive form of MS had an EDSS score higher than 4.5, which
means that they could not walk without aids, in 2013, only the 60% of patients with PPMS
belonged to this group (EDSS: 4.5-9). 26% of patients with PPMS have even better functional
status with an EDSS between 2 and 3.5. This change happened due to the new diagnostic
criteria of MS by Polman, which enabled us to diagnose PPMS at the onset of the disease
(Polman et al., 2005).
There are several factors – both environmental and genetic -  which contribute to the
etiology  of  MS.  According  to  data  of  the  International  Multiple  Sclerosis  Genetics
Consortium  (IMSGC),  there  are  over  a  hundred  associated  genetic  loci  confirmed  that
contribute to MS (IMSGC et al., 2013). It is also known that the disease shows a geographical
distribution from the Equator to the north (Simpson et al., 2011). Hungary is a middle-risk
area for MS. In high-risk regions, the relative risk of first-degree relatives in familial cases is
between 5 and 10% (Ebers et al., 1995). 
In 1996 in the United Kingdom, a cross-sectional study was performed, in which 19%
of the patients with MS were reported to have effected relatives. The age-adjusted risks for
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first-,  second-  and  third-degree  relatives  of  patients  were  2.77%,  1.02%  and  0.88%
respectively (Robertson et al., 1996). 
In France, the crude overall MS recurrence risk was lower than in the UK or in Canada
examined with a similar methodology. According to these data, 9.8% of patients had a relative
with MS (Sazdovitch et al., 2000). 
Two  studies  examined  the  familial  recurrence  of  MS  in  Sardinia,  which  is
characterized  by  high  disease  incidence  and  prevalence  of  MS.  Here,  the  age-adjusted
recurrence risk for relatives of patients with MS was 1.9% (Marruso et al., 2002; Prokopenko
et al., 2003). Nielsen et al. (2005) estimated the lifetime risk of patients with MS to 2.9% in
female and to 2.8% in male first-degree relatives of patients with MS. 
In Argentina, where the prevalence of MS ranged from low to intermediate, 10% of
the patients with MS were reported to have at least one relative with MS (Farez et al., 2014).
Another  study  on  the  familial  accumulation  of  MS  from  the  southern  hemisphere  was
performed in Australia. The familial recurrence risk of MS was found to be lower than that in
the northern hemisphere, which may be related to the lower population prevalence of MS. The
age-adjusted  risk  for  siblings  was  2.13%,  however,  the  overall  genetic  susceptibility  was
similar  to  that  on  the  northern  hemisphere,  which  can  be  explained  with  the  different
environmental factors (O'Gorman et al., 2011). 
A meta-analysis of more than 500 studies on the familial risk in MS was conducted by
O'Gorman et al. in 2013. The overall recurrence risk was 18.2% for monozygotic twins, and
2.7% for siblings. These data show a significantly higher recurrence risk for dizygotic twins
compared to siblings. This may suggest either an environmental risk factor, or an intrauterine
effect. In addition, they concluded that the known 57 MS loci are responsible for only quarter
of the familial cases. This meta-analysis demonstrated that there is a consistent evidence for
the  latitudinal  gradient  in  the  recurrence  risk  in  case  of  all  relatives  at  adult  ages.  This
latitudinal gradient is absent in the recurrence risks of younger generations, which suggests
that the emergence of disease has a stronger genetic determination in these cases. This is also
supported by the results of an earlier study, which demonstrated, that the younger age at the
onset of MS is related to the HLA DRB1*15:01 allele (Hensiek et al, 2002). 
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In Sweden, thanks to the Swedish Multiple Sclerosis Registry, a nationwide hospital
registry, the national Multi-Generation Registry and the Swedish Twin Registry, there was an
opportunity to conduct a comprehensive study on familial MS recurrence risk  based on about
15 million  people  living  in  Sweden (Westerlind  et  al.,  2014).  The  age-adjusted  risk  was
17.26% for  monozygotic  twins,  1.69%  for  dizygotic  twins  and  2.29% for  siblings.  The
relative risk was 23.62 for monozygotic twins, and 7.13 for siblings. These data show a lower
familial relative risks in MS than previously reported. 
Our study involved 1500 patients with MS, which is almost 25% of all Hungarian
patients with MS. The ratio of the familial cases was 2%, which is significantly lower than
data in the literature. This difference can be explained by the lower prevalence rate in this
region.  The different frequency and inheritance of susceptibility and resistance alleles may
provide an alternative explanation for this low number of familial cases. In our study, we
examined first-degree relatives only. Due to the low number of patients, we could not perform
a subgroup analysis based on the degree of relativeness. Despite this fact, we believe that our
study was important, since this was the first study on the familial risk of MS in a middle-risk
population. 
The  researches  of  the  last  ten  years  pointed  out  the  importance  of  the  unseen
symptoms of MS, such as fatigue and depression, as well  as their  effects on the patients'
health-related  quality  of  life.  In  2012,  we  started  a  multicentre,  cross-sectional  study in
Hungary to estimate how frequent the fatigue and the depression are among patients with the
relapsing-remitting form of MS and how these factors influence the patients' health-related
quality  of  life.  We  selected  patients  treated  with  glatiramer  acetate,  since  the  chance  of
secondary  fatigue  is  much  lower  in  case  of  this  treatment,  than  in  patients  treated  with
interferon beta treatment. Furthermore, unlike in the case of interferon beta, the side-effects of
glatiramer acetate do not include depression (Plosker, 2011). 
Considering the data of our prevalence study (the standardized prevalence of MS in
Csongrád County is  83.7/100,000, 69% of the patients have RRMS and 78% of the patients
with RRMS are treated with disease-modifying therapy), the 428 patients examined in our
study represent almost 10% of the Hungarian MS patients treated with disease-modifying
41
therapy, and more than 50% of the Hungarian MS patients treated with glatiramer acetate.  
Our data on the prevalence of fatigue (62.4% after a mean disease duration of 11.23
years) are in line with the literature data (Lerdal et al., 2003). According to data gained by
previous studies, the prevalence of depression among patients with MS is between 36% and
54% (Ziemssen, 2009). The risk factors for depression in MS include the female gender, an
age under 35 years,  a family history of major depression and stress (Patten et  al.,  2000).
Chwastiak et al. (2002) showed that depression correlates with a lower level of education, a
younger age and the absence of social  support. However a study in Sarajevo, Bosnia and
Herzegovina confirmed that depression is  more frequent among younger and middle-aged
patients with a higher educational level and an unmarried status (Alajbegovic et al., 2011). In
the general population, depression is 1.7 to 2 times more frequent in females than in males
(Kessler et al., 1993). The above-mentioned studies did not support this ratio in patients with
MS. 
Surprisingly,  in  our  study,  the  prevalence  of  depression  was  significantly  lower
(13.4%) than found by previous studies. The low prevalence of depression in our study may
result from several factors. The majority of the respondent patients lived in family, with one
or two children. However, about 70% of the patients did not answer the questions on their
family status. In Hungary, there is a freely available phone service with the contribution of
multiple sclerosis nurses. This, together with the usual medical examinations ensure stable
and well-functioning medical support for patients with MS. The participants in this study
suffered from a low level of disability (low median EDSS score). Furthermore, glatiramer
acetate  treatment  is  known  not  only  to  reduce  the  activity  of  MS,  but  also  to  have  an
antidepressant effect (Tsai, 2007; Johnson, 2012). Due to these facts, it is very important to
introduce this therapy as soon as possible after the onset of MS. 
The  diagnosis  and  effective  therapy  of  depression  are  extremely  important,  since
depression significantly worsens the patients' health-related quality of life, and can also mask
the effects of the other factors, such as fatigue, the disability, as well as the duration of MS on
quality of life, as demonstrated by our correlation analysis. Depression is also an important
factor in the choice of disease-modifying therapy, since depression is listed among the adverse
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events of interferon beta therapy (Plosker, 2011). Finally, due to the ineffective treatment of
depression,  the  level  of  the  patient's  compliance  may  decrease,  which  may  lead  to  the
cessation  of  disease-modifying  therapy.  Despite  these  facts,  recent  studies  showed  that
depression in MS is not diagnosed and treated effectively (McGuigan, & Hutchinson, 2006;
Marrie et al., 2009).
In the past decade, several studies showed that fatigue and depression together with
the disability and the disease duration significantly influence the health-related quality of life
of patients with MS (Miller et al., 2003; Pittion-Vouyovitch et al., 2006). Furthermore, recent
studies from Iran and Poland yielded results on the influence of fatigue and depression on the
health-related quality of life in MS which are similar to those found in our study (Kargarfard
et al., 2012; Papuc, & Stelmasiak, 2012).
Several previous studies confirmed that fatigue decreases the health-related quality of
life significantly (Benedict et al., 2005; Janardhan & Bakshi, 2002; Lobentanz et al., 2004;
Mitchell et al., 2005). In these studies, fatigue was examined as a one-dimensional factor. In
our study, we used a new approach to examine the three dimensions of fatigue separately. Our
partly  contradictory  and  surprising  results  which  indicate  that  physical  fatigue  does  not
predict the health-related quality of life of patients with MS, can be explained by this new
approach. 
However, social and cognitive fatigue have significantly negative effects on the quality
of life. We believe that our results are important, since these factors cannot be measured by
EDSS, and the patients do not talk willingly about their social and cognitive difficulties, as
they do not find this important. However, decreasing their social or cognitive fatigue may lead
to the improvement of their quality of life. 
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VI. Conclusions
In our studies, we investigated the prevalence of MS in Csongrád County, the familial
rate of MS in Hungary and the prevalence of fatigue and depression, as well as their effects on
the patients'  health-related quality of life.  Knowing the number of patients with MS in a
geographical area allows us to estimate their number in the country. This helps to estimate the
treatment costs, the effect of the different therapies on the natural history of the disease, as
well as the conditions of the patients. To estimate the prevalence, a precise diagnosis and a
well-defined geographical location are essential. Earlier, the diagnosis of MS was based on
the Poser criteria.  Our prevalence study was the first  in Hungary to apply the McDonald
criteria.  We  found  that  the  standardized  prevalence  was  83.7/100,000,  which  means  that
Hungary is one of the medium-risk countries.
The onset of MS happens mostly at a young age.  The question of heritability is very
important for the patients. MS is a complex disease, its cause is unknown. Currently, more
than 100 genetic loci and several environmental risk factors are confirmed to be related to the
susceptibility for MS. In our familial epidemiological study, we involved 1500 patients with
MS in Hungary, which was almost 25% of all the patients with MS in the country. The ratio of
the familial cases was 2%. Due to the low number of patients,  it was not possible to perform
a subgroup analysis, however, in a middle-risk region, our study was the first that investigated
familial risk in MS. 
In our study, the prevalence of fatigue was 62.4%, which is in line with the data in the
literature.  The prevalence of depression was 13.4%, which is lower than it  was found by
earlier studies. The explanation for this may be the supporting medical and familial milieu,
which  surrounds  the  patients  with  MS in  Hungary.  We confirmed  that  the  health-related
quality of life of non-fatigued patients with MS is better than that of fatigued patients. We
found that depression may escalate the negative effects of the other factors on the quality of
life. Our study drew attention to the importance of the social and cognitive fatigue, which can
be hidden in the common medical examinations, however, besides the level of disability, these
factors significantly worsen the patients' health-related quality of life in case of MS.
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Objective – Recent epidemiological studies were mainly based on the
Poser or other diagnostic criteria. There have been no previous data
from Hungary, which were assessed with the more up-to-date
McDonald criteria and which give comparable standardized data from
the region. Materials and Methods – Data were collected from the MS
Register of the Department of Neurology at the University of Szeged.
All possible and definitive patients with MS living in the county on
the prevalence day were included in the study. Direct standardization
was based on the European standard population. Results – On 1
January 2013, 379 registered patients with MS were alive in the
county, that is, a crude MS prevalence of 89.8/100,000, 46.6/100,000
in males and 128.6/100,000 in females; standardized prevalence:
83.7/100,000 (42.3/100,000 for males, 122.6/100,000 for females). The
distribution of the clinical forms: 11% clinically isolated syndrome,
69% relapsing–remitting form, 14% secondary progressive form, 6%
primary progressive form. Patients with no or only mild symptoms
comprised 91.9% of the relapsing–remitting population.
Conclusions – This is the first standardized epidemiological study
based on the McDonald criteria in Central Europe. Hungary is a
medium-risk country as concerns the prevalence of MS. The crude
prevalence appears to have increased relative to previous reports from
the county.
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Introduction
Multiple sclerosis (MS) is the most common
autoimmune, demyelinating and neurodegenera-
tive disease of the central nervous system among
young adults. Epidemiological studies not only
reveal the number of patients, but also draw
attention to aetiological factors. Previous studies
have presumed the roles of a genetic predisposi-
tion, infections and vitamin D deficiency in the
development of MS (1–4). The disease has a
north–south gradient in Europe, decreasing
towards the equator. The improved diagnostic
facilities and longer survival of patients with MS
also probably explain to some extent the increas-
ing prevalence in the past 60 years (5).
The diagnosis of MS is still a clinical diagno-
sis, which is then confirmed via paraclinical
examinations. A precise diagnosis and a well-
defined geographical location are essential as
concerns epidemiological studies. Comparison of
the findings of different epidemiological studies is
limited because of the use of different diagnostic
criteria and methodologies; moreover, the major-
ity of these studies provide crude estimates (6).
Recent epidemiological studies have focused on
solving the discrepancies caused by diversities in
age, sex and ethnic attribution of different popu-
lations to explore a global image of the epidemi-
ology of MS.
Most studies of the epidemiology of MS have
been carried out with the Poser or earlier diag-
nostic criteria (7). The various McDonald crite-
ria, based on MRI findings, were introduced in
2001, 2005 and 2010 (8–10). Thanks to these
criteria, the diagnosis of MS can be made
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immediately after the recognition of the first
symptom, and the time between the first relapse
and the definitive diagnosis is therefore shorter.
Research involving the McDonald criteria is not
common (7). There has been no epidemiological
study in Hungary in which the McDonald diag-
nostic criteria were used. The aim of this study
was to determine the age- and sex-specific crude
and standardized prevalence of MS in Csongrad
County on the chosen prevalence day (1 January
2013) according to the McDonald criteria to
obtain comparable data from the region.
Materials and methods
Study area
Csongrad County is located in the south-eastern
region of Hungary between latitudes 46° 1′ and
46° 8′ and longitudes 19° 6′ and 20° 7′, in the tem-
perate zone, with an area of 4262.68 km² (Fig. 1).
The climate is humid continental. According to
the latest census performed by the Hungarian
Central Statistical Office in 2011, 421,827 people
lived in Csongrad County: 199,388 males and
222,439 females, Hungarians accounting for 85%
of the population (source: ksh.hu).
Patients
The Department of Neurology at the University
of Szeged has an MS outpatient unit for the
inhabitants of Csongrad County, which has
maintained an MS register containing regularly
updated patient records since 1996. All suspected
MS cases are referred to the MS Centre at the
University from the region of the Southern Great
Plain to confirm or exclude the diagnosis. The
diagnosis was established by neurology special-
ists, who applied the criteria of Poser until 2001,
but subsequently the criteria of McDonald were
introduced and the medical records on MRI are
the responsibility of a neuroradiologist (8–10).
All patients with diagnoses of MS (ICD-9 code
340) according to Poser were reviewed according
to the McDonald criteria. The patients are exam-
ined every 3 months, with checks on their neuro-
logical status, their Expanded Disability Status
Scale (EDSS) score and the clinical form of the
disease (11). All patients participate in brain
MRI and, if necessary, spinal cord or optic nerve
MRI examination. Cerebrospinal fluid samples
are analysed in our accredited laboratory (accord-
ing to ISO 9002) by means of laser nephelometry
for the quantitative determination of proteins,
isoelectric focusing and IgG immunoblotting to
detect oligoclonal bands. Since 2001, patients
with the clinically isolated syndrome (CIS) partic-
ipate in control MRI examinations 3 and
6 months after the appearance of the first symp-
tom. As long as the MRI does not indicate new
lesions, control examinations are carried out
every 3 months. Patients with clinically definitive
MS take part in neurological control examina-
tions every 3 months and brain MRI examina-
tions yearly. Disease-modifying-treated patients
have brain MRI examinations yearly in the first
2 years of the therapy, and subsequently only if a
new relapse occurs. Unscheduled visits are made
in the event of a relapse, and the neurological
status and EDSS score are recorded. Three neu-
rology specialists independently excluded those
who had earlier been presumed to have MS, but
whose diagnosis was ruled out during the revision
Figure 1. Csongrad County, located in the south-eastern region of Hungary.
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of the hospital archives. Once the diagnosis was
established, the patient’s medical history, contain-
ing their relapse rate, EDSS score, paraclinical
examinations data, clinical form and date of
onset, was recorded in the MS registry. Deaths
were identified from pathological records and
certificates of death.
In this cross-sectional study, we included all
patients with clinically isolated and clinically
definitive MS living in the area on the prevalence
day. To allow a well-defined, unified epidemiolog-
ical study, only patients living in the county on
the prevalence day were included.
The patients with the relapsing–remitting form
were in a stable neurological state and in remis-
sion on the chosen prevalence day. The duration
of the disease was calculated from the time of
appearance of the first symptom.
The female/male ratio, the proportion of each
clinical form, the number of new patients, the
number of patients who migrated from this geo-
graphical area during the intervening period and
the frequency data relating to the various dis-
ease-modifying treatments (DMTs) were also
documented. Age- and sex-adjusted prevalence
was calculated by the direct method of standardi-
zation with the use of the European Standard
Population as reference (12). The study was
approved by the Human Investigation Review
Board of the University of Szeged (approval
number 3267) in accordance with the Helsinki
Declaration.
Results
The MS register listed 249 patients with MS in
1999. Between 1999 and 2013, 259 new MS cases
were diagnosed. In that period, 86 patients died
and 30 moved away from the geographical area.
The diagnosis of 13 patients was revised, as the
longitudinal follow-up eventually ruled out MS
(seven patients had neuromyelitis optica, and six
patients had autoimmunity-related vasculitis).
The most recent Hungarian Central Statistical
Office data indicated that 421,827 people lived in
Csongrad County (199,388 males and 222,439
females), and 379 patients with MS were regis-
tered as being alive on the day of prevalence
determination, 1 January 2013. On the basis of
these data, the crude prevalence of MS was
89.8/100,000, 46.6/100,000 among males and
128.6/100,000 among females. The standardized
prevalence was 83.7/100,000 for the overall MS
population, 42.3/100,000 for men and 122.6/
100,000 for women. The age- and sex-adjusted
prevalence data are detailed in Table 1. The
female/male ratio was 3.08 in the MS population
and 1.12 in the overall county population.
The documented distribution of the clinical
forms was 11% (n = 44) with the CIS, 69%
(n = 260) with the relapsing–remitting form, 14%
(n = 52) with the secondary progressive form and
6% (n = 23) with the primary progressive form
(Fig. 2).
The average duration of the disease for the
CIS cases was 4.7 years 4.0 (range: 0–17), for
the relapsing–remitting cases was 12.9 years 9.1
(range: 0–55), for the secondary progressive cases
was 21.7 years 9.4 (range: 4–47) and for the pri-
mary progressive cases was 8.5 years 5.9 (range:
1–23). The average age at the onset of the disease
was 31.4 years 9.6 (range: 19–61) in the CIS
group, 31.7 years 9.1 (range: 5–59) in the
relapsing–remitting group, 35.4 years 12 (range:
13–64) in the secondary progressive group and
47.3 years 8.8 (range: 20–61) in the primary
progressive group.
The average EDSS score in the CIS group was
0.4  0.6. In the relapsing–remitting group,
91.9% (n = 239) had EDSS scores in the range
0–4, and 8.1% (n = 21) had scores of 4.0–6.5. In
the secondary progressive group, 53.8% (n = 28)
of the patients had EDSS scores of 4.0–6.5
points, and 46.2% (n = 24) had scores of ≥7. In
the primary progressive group, 26.1% (n = 6) had
EDSS scores of 2–3.5, 13% (n = 3) had a score
of 4, 34.8% (n = 8) had scores of 4.5–6.5, and
26.1% (n = 6) had scores of ≥7 (Table 2).
Table 1 Sex- and age-specific prevalence of multiple sclerosis in Csongrad
County on 1 January 2013
Age groups
(years)
Men Women Total
Cases Prevalence Cases Prevalence Cases Prevalence
15> 0 0.0 0 0.0 0 0.0
15–19 0 0.0 2 16.4 2 8.0
20–24 3 20.4 9 62.8 12 41.4
25–29 14 92.1 22 147.0 36 119.3
30–34 9 50.4 24 141.3 33 94.7
35–39 10 60.4 38 238.0 48 147.6
40–44 15 103.6 37 259.5 52 180.9
45–49 5 41.5 27 214.8 32 130.0
50–54 9 68.3 41 276.5 50 178.6
55–59 14 97.4 32 187.4 46 146.3
60–64 9 76.5 29 193.0 38 141.9
65–69 2 21.0 15 114.8 17 75.2
70< 3 17.0 10 0.0 13 25.7
Crude 93 46.6* 286 128.6* 379 89.8*
Age-sex-
adjusted
42.3† 122.6† 83.7†
*Crude prevalence per 100,000 population.
†Standardized prevalence per 100,000 population (The European Standard was
used as reference population in the direct standardization).
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The patients with the relapsing–remitting form
comprised 73.1% of the MS population who reg-
ularly received DMTs. Those who received any
kind of DMTs in the first 5 years after the diag-
nosis was established had an average EDSS score
of 1.1  1.0 (range: 0–3.5), and those who
received it between 5 and 10 years after the diag-
nosis had an average EDSS score of 1.8  1.3
(range: 0–5.5). The average EDSS score among
the patients who spent 10 years or more without
therapy after the diagnosis was 2.1  1.1 (range:
0–4).
Discussion
Recent epidemiological studies focusing on the
prevalence of the disease have attempted to solve
the discrepancies in terms of the differences in the
methodologies used, the ethnic origins, the geo-
graphical areas and the age distributions in the
various study populations. One possibility to
solve some of these differences and obtain uni-
form comparable results is sex and age adjust-
ment for a standard population (13).
As regards the occurrence of MS, Hungary is
one of the medium-risk countries. The first epide-
miological study in Hungary, by Halasi in 1961,
revealed a crude prevalence of 20/100,000. The
crude prevalence in Baranya County in 1983 was
reported by Palffy et al. (14) to be 37/100,000,
and the epidemiological study by Bencsik et al.
(15) in Csongrad County in 1999 revealed a crude
prevalence of 62/100,000. Our present study indi-
cated a crude prevalence in Csongrad County of
89.8/100,000 and a standardized prevalence of
83.7/100,000.
Prevalence studies based on the McDonald
criteria adjusted to the European standard popu-
lation have been published from Osona, Spain,
where in 2008 it was 74/100,000, from Verona,
Italy, where it was 96/100,000 in 2001, and from
France, where it was 94.7/100,000 in 2004. Our
data are in line with these reports (16–18).
Prevalence data from areas closer to Hungary
are not common. An epidemiological study from
Belgrade, Yugoslavia, in 1996 revealed a preva-
lence of 41.5/100,000, but it was performed
according to the Poser diagnostic criteria and
adjusted to the world population (19). A study
from western Herzegovina in 2003, based on the
McDonald criteria and standardized to the Euro-
pean population, revealed a prevalence of 26.9/
100,000 (20). Our result is higher, probably
because those data were published more than
10 years previously. In 1999, a study from Croa-
tia and Slovenia with the European population as
standard indicated that the age-adjusted preva-
lence was 156.1/100,000 according to the Poser
diagnostic criteria; this is much higher than we
reported (21).
Epidemiological studies from Scandinavia are
relatively common. In 2002 in Oppland County,
Norway, the age-adjusted prevalence was 185.6/
100,000; in Vest-Agder County, Norway, in 2007,
it was 186/100,000 (22, 23). All Scandinavian
studies took into consideration all probable and
possible MS cases according to the Poser criteria
and the standardized data to the European popu-
lation as reference. In 1990, in V€asterbotten
County, Sweden, with use of Poser diagnostic cri-
teria, the age-adjusted prevalence to the Euro-
pean standard population was 126/100,000, but
patients with a diagnosis of only probable MS
were excluded (24). As expected, our data are
lower than those reported from the northern
region of Europe, which is in line with the geo-
graphical distribution of the disease described by
Dean, and the introduction of national registries
in these countries may lead to better and more
precise case assessment (25).
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Figure 2. Distribution of clinical forms of MS in Csongrad
County. CIS, clinically isolated syndrome; R-R, relapsing–
remitting; SP, secondary progressive; PP, primary progres-
sive.
Table 2 Distribution of patients in Csongrad County by EDSS scores in the
clinical forms of the disease on the day of prevalence determination
Clinical form EDSS scores
Number
of patients
Percentage within
the clinical form (%)
Relapsing–remitting 0–4 239 91.9
4.5–6.5 21 8.1
≥7 0 0
Secondary progressive 4–6.5 28 53.8
≥7 24 46.2
Primary progressive 2–3.5 6 26.1
4 3 13
4.5–6.5 8 34.8
≥7 6 26.1
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In our own study, the female/male ratio was
1:3.08 in the MS population and 1:1.12 in the
county population, while the standardized preva-
lence was 122.6/100,000 among women and 42.3/
100,000 among men. In 1999, Bencsik et al. (15)
reported that the female/male ratio was 1:2.75 in
the MS population of the county and 1:1.09 in the
overall county population. These results are in
accordance with the literature finding of a higher
occurrence of MS in women and with those that
show an increasing tendency (26, 27).
Among patients with the relapsing–remitting
form, who accounted for 68.6% of the overall
MS population, the average disease duration was
12.9 years, and 91.9% had no or only mild symp-
toms. DMTs were introduced in Hungary in
1996. In fact, 73.1% of the patients with the
relapsing–remitting form receive some type of
DMTs. The progression of the disease is slower;
the proportion of patients in good physical condi-
tion increases and the quality of life improves in
consequence of the therapy. The change to the
secondary progressive form shifts to an older
stage of life, and the patients can remain at work
for a longer time, which is important because MS
tends to affect young people. Similar results have
been reported from Poland, where, without the
disease-modifying therapy, 40% of the patients
suffered from the severe secondary progressive
form in 2004, whereas the number had decreased
to 16% by 2010, after the introduction of immu-
nomodulatory treatment (28, 29).
The frequency of the primary progressive form
was 6.1%, which is lower than previously reported.
This may be due to the death of older patients with
severe disability. However, it should be mentioned
that the patients with a better functional status in
this clinical form (EDSS scores of 3.0–3.5) com-
prise 26% of the population. The earlier lack of a
protocol meant that the definitive diagnosis of the
primary progressive form usually took years. The
application of the diagnostic criteria system of Pol-
man et al. (9) allows the diagnosis to be established
at the beginning of the illness, when the impair-
ment is milder. The importance of the earlier diag-
nosis resides in the future possibility of the
medication of this clinical form.
An important limitation of the study is that the
population of Csongrad County with 421,827
inhabitants is a low population number, but it
comprised 4.2% of the whole population of Hun-
gary (9,985,722 persons according to the latest
census performed by the Hungarian Central
Statistical Office in 2011).
We conclude that, as regards the occurrence of
MS, Hungary is one of the medium-risk countries.
The current study appears to have been the first in
Hungary that was performed with the McDonald
criteria and that has provided standardized preva-
lence data from the region and the opportunity to
establish prospective follow-up studies to identify
the real pattern of MS.
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Background: The common symptoms of multiple sclerosis are fatigue, depression, cognitive dysfunction,
pain and sexual dysfunction, which inﬂuence the health-related quality of life of the patients.
Objective: We aimed to determine the correlations between the health-related quality of life, the level of
disability, fatigue and depression in glatiramer acetate-treated patients with multiple sclerosis in Hun-
gary.
Methods: The Hungarian versions of the Multiple Sclerosis Quality of Life-54, Fatigue Impact Scale and
Beck Depression Inventory questionnaires were completed by 428 relapsing-remitting multiple sclerosis
patients treated with glatiramer acetate from 19 Hungarian centers.
Results: The prevalence of fatigue was found to be 62.4%. The prevalence of depression was lower (13.4%)
than that described in previous studies (36–54%) among patients with multiple sclerosis. Signiﬁcant
differences in the health-related quality of life were found between fatigued and non-fatigued patients.
The level of disability, fatigue, depression and the duration of the disease correlated signiﬁcantly with the
quality of life. However, linear regression analysis indicated that the quality of life was predicted by the
level of disability, depression, social and cognitive fatigue, but not by physical fatigue.
Conclusions: Decreasing the disease activity in multiple sclerosis with immunomodulatory therapy, to-
gether with improvements of the diagnostics and treatment of the accompanying depression and fatigue
are of high priority to improve the health-related quality of life of patients with multiple sclerosis.
& 2016 Elsevier B.V. All rights reserved.
1. Introduction
Multiple sclerosis (MS) is a chronic disease, which, via its var-
ious symptoms, impairs the patients’ ability to move and work, as
well as their level of well-being. Although the Expanded Disability
Status Scale (EDSS) is generally used to determine the level of
disability of patients with multiple sclerosis, several aspects of
multiple sclerosis are not measurable with this scale (Kurtzke,
1983). In recent years, measurement of the health-related quality
of life (HRQoL) became a useful tool to assess the burden of MS.
HRQoL is a multidimensional parameter which relates to physical,
mental and social health, and which is estimated by using general,
combined and speciﬁc questionnaires (Hadgkiss et al., 2013). The
common symptoms of multiple sclerosis are fatigue, depression,
cognitive dysfunction, pain and sexual dysfunction, which sy-
nergistically inﬂuence the health-related quality of life (Crayton
et al., 2004).
Fatigue is found in 40–90% of patients with multiple sclerosis
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(Lerdal et al., 2003), and fundamentally inﬂuences their daily
routine. The patients’ capability of moving is better during the
morning hours, but they need resting periods during longer ac-
tivities. Fatigue also limits the patients’ personal interactions;
moreover, it can even lead to losing their jobs. A patient with
multiple sclerosis was reported, who presented fatigue as the only
manifestation of an acute MS relapse (Flachenecker and Meissner,
2008). Futhermore, in another study, the correlation of fatigue and
a cognitive sign of MS, alertness, was conﬁrmed (Weinges-Evers
et al., 2010). Three forms of fatigue have been described: physical,
cognitive and social fatigue (Bakshi, 2003; Vucic et al., 2010).
The diagnosis and treatment of depression are essential in
multiple sclerosis cases. Patten et al. concluded that major de-
pression occurs in 15.7% of individuals with multiple sclerosis,
which means a 2.3 times higher risk than in the normal population
(Patten et al., 2003). A survey by Ziemssen et al. suggested that
major depression may occur in approximately 50% of patients with
multiple sclerosis (Ziemssen, 2009). Only a small proportion of
patients with multiple sclerosis receive effective treatment for
their depression, and this situation, besides putting their unin-
terrupted immunomodulatory therapy at risk, can lead to more
severe fatigue, with a resulting negative inﬂuence on their health-
related quality of life (Sadovnick et al., 1996).
Among the various modes of immunomodulatory therapy, the
interferons can cause ﬂu-like symptoms and fever, which can lead
to secondary fatigue (Plosker, 2011). Sleep disorders can also cause
secondary fatigue. Studies showed that sleep medical therapy may
improve MS related fatigue (Veauthier et al., 2013; Veauthier and
Paul, 2014). Furthermore, one of the adverse events of interferon
beta treatment is depression. It was suggested that interferon beta
induces secondary depression due to inhibition of serotonin pro-
duction, however, long-term studies did not prove this hypothesis
(Loftis and Hauser, 2004; Reder et al., 2014). For our study, we
selected a group of glatiramer acetate-treated patients with mul-
tiple sclerosis, since the adverse events of glatiramer acetate (de-
pression, ﬂu-like symptoms, fever) are less common than those of
interferon beta.
The aim of our study was to determine the prevalence of fati-
gue and depression in glatiramer acetate-treated patients with
multiple sclerosis. Since we expected that fatigue negatively in-
ﬂuences the health-related quality of life, we compared this
parameter in fatigued and non-fatigued patients. We analyzed the
correlation of fatigue, depression, clinical disability and the disease
duration with the health-related quality of life.
2. Methods
2.1. Participants
Data on 428 relapsing-remitting patients with multiple
sclerosis treated with glatiramer acetate were collected from 19
Hungarian multiple sclerosis centers. The relevant socio-demo-
graphic and disease-related data were obtained from the multiple
sclerosis registers at the centers. The diagnosis was conﬁrmed
according to the 2005 modiﬁcation of the McDonald criteria for
relapsing-remitting multiple sclerosis (McDonald et al., 2001;
Polman et al., 2005). Patients were included in the study according
to the following inclusion criteria: the patients had a relapsing-
remitting form of multiple sclerosis, glatiramer acetate treatment
period was longer than one year, the patients were in remission
for at least 30 days, the patients were off steroid therapy for more
than 30 days, the patients had an EDSS score between zero and
5.5, and the patients were more than 18 years old.
2.2. Ethics
The personal data on the patients were subject to strict con-
ﬁdentiality. All participants received appropriate information
about the study both in written form and orally. They gave their
written consent to statistical evaluation of their answers. The
study was approved by the Science and Research-ethics Commit-
tee of the Medical Science Council in Hungary (3462-0/2010-
1018EKU (197/PI/10)) and was in full accord with the Declaration
of Helsinki. The same, ethically approved information sheet and
consent form were given to the participating patients at each
center.
2.3. Measures
The most frequently utilized questionnaire in multiple sclerosis
to measure quality of life is the Multiple Sclerosis Quality of Life
Questionnaire (MSQoL-54), which is a combined questionnaire,
developed for English-speaking patients. It contains general
questions regarding the quality of life (Short Form-36) and 18
speciﬁc questions for patients with multiple sclerosis (Vickrey
et al., 1995). The MSQoL-54 enables the comparison of the quality
of life of patients with multiple sclerosis with that of the general
population and with that of patients with other diseases. The total
of 54 questions can be divided into 14 groups: Physical health, Role
limitations due to physical problems, Role limitations due to
emotional problems, Pain, Emotional well-being, Energy, Health
perceptions, Social function, Cognitive function, Health distress,
Overall quality of life, Sexual function, Satisfaction with sexual
function and Change in health. The MSQoL-54 was validated for
the Hungarian language (Füvesi et al., 2008), and the ﬁrst survey
with this questionnaire was performed in Hungary in 2010 (Füvesi
et al., 2010). Apart from determining the health-related quality of
life of multiple sclerosis patients, the survey demonstrated that
62% of the patients had at least one concomitant disease. De-
pression was found in 20.3% of the patients with multiple sclerosis.
The pathophysiology of fatigue is not well understood, and the
objective characterization of fatigue is difﬁcult. Recently, it was
shown that fatigue is associated with the alterations of basal
ganglia functional connectivity and with altered parameters of
saccade like ocular motor movements, therefore testing these may
lead to a better quantiﬁcation of fatigue (Finke et al., 2012, 2015).
However, questionnaires are widely used for this purpose. Al-
though they are somewhat subjective, they yield useful informa-
tion about the patients’ everyday life. The most frequently used
questionnaires are the Fatigue Severity Scale (FSS) (Krupp et al.,
1989), the Fatigue Impact Scale (FIS) (Fisk et al., 1994), and the
Modiﬁed Fatigue Impact Scale (MFIS) (Achiron et al., 2015). While
the FSS is one-dimensional, measuring only physical fatigue, the
FIS and MFIS assess all three aspects of fatigue. The completed FIS
questionnaire contains 40 statements, the MFIS is a 21-item scale,
each with a score ranging from 0 to 4 points, giving information on
the last 4 weeks. The Hungarian version of the FIS was validated in
2011 (Losonczi et al., 2011).
The Beck Depression Inventory-First Edition (BDI-I.) provides
21 grouped assertions on how the patient has been feeling in the
last week. Each question has a set of at least four possible answers.
With a total score above 21 points, the patient is regarded to have
depression (Beck et al., 1961).
2.4. Statistical analysis
Statistical analysis was carried out with the Statistical Package
for Social Sciences (SPSS 19.0, SPSS Inc., http://www.spss.com); the
level of signiﬁcance was predeﬁned at po0.05. For determination
of the prevalence of fatigue and depression, we used frequency
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analysis. Correlation coefﬁcients and partial correlation coefﬁ-
cients were applied to assess the inﬂuence of the EDSS score,
depression, fatigue and the disease duration on the quality of life.
The predictors of the quality of life were determined by linear
regression. The data on the fatigued and the non-fatigued patients
were compared with the independent samples t-test. Our study is
an exploratory pilot study, so no correction for multiple compar-
isons was made.
3. Results
3.1. Demographic and clinical measures
The average age of the patients was 43.6 years (95% conﬁdence
interval [CI] 42.6–44.6), the male to female ratio was 1:2.8, the
mean disease duration of multiple sclerosis from date of diagnosis
was 11.2 years (95% CI 10.6–11.9), the mean duration of glatiramer
acetate treatment was 6.6 years (95% CI 6.2–6.9) and the median
EDSS score was 2.0 (95% CI 2.2–2.5). The percentage of the married
respondents was 60.7%, and 83.8% had one or two children.
Around 66% had participated successfully in secondary education,
and about 33% had done so in higher-level education. The dis-
tribution of patients among the multiple sclerosis centers is shown
in Table 1.
3.2. Main outcome measures
As concerns the responses to the MSQoL-54, FIS and BDI
questionnaires by the 428 glatiramer acetate-treated relapsing-
remitting patients with multiple sclerosis in this multicentre
study, 402 and 381 patients answered all questions in the FIS and
BDI questionnaires, respectively. In each question group of the
MSQoL-54, an average of 60 of the questionnaires could not be
evaluated because of missing data. An exception was the question
group relating to the sexual function and the satisfaction with the
sexual function, which were incomplete in more than 80 cases.
The FIS scores indicated that the prevalence of fatigue was
62.4% (251 of 402 patients). The prevalence of depression was
13.4% (51 of 381 patients). Among the 278 patients who ﬁlled in
both questionnaires completely, no one had depression without
fatigue. However, 35 of the 168 fatigued patients also had de-
pression (20.8%). Non-fatigued patients assessed their health-re-
lated quality of life signiﬁcantly higher than patients with fatigue
in all question groups of the MSQoL-54 questionnaire (Table 2).
By means of correlation analysis, we examined the correlation
of the EDSS score, depression, the three dimensions of fatigue and
the disease duration with the health-related quality of life, as ex-
amined with the MSQoL-54. Depression and the three dimensions
of fatigue inﬂuenced all the subscales of the MSQoL-54 questions
signiﬁcantly negatively. The EDSS score correlated signiﬁcantly
negatively with all aspects of the MSQoL-54, except for the cog-
nitive function scale. The disease duration had a signiﬁcant ne-
gative correlation with the quality of life, with the exception of the
mental health, the cognitive function and the satisfaction with the
sexual function (Table 3).
Regression analysis revealed that the overall quality of life was
signiﬁcantly predicted by the EDSS score, depression and social
fatigue (Table 4). When the patients were grouped on the basis of
the presence of depression, it emerged that in patients with de-
pression, social fatigue was the only factor that predicted the
quality of life (Table 5). At question 54 of the MSQoL-54, the pa-
tients verbally evaluate their quality of life (terrible (1)-unhappy
(2)-mostly grumbler (3) -mixed (4)-mostly satisﬁed (5)-satisﬁed
(6)-happy (7)). Regression analysis showed that the verbal char-
acterization of the quality of life was predicted by the EDSS score,
depression, social and cognitive fatigue (R2¼0.389, po0.05). As
concerns the cognitive and the sexual quality of life, we found
signiﬁcant effects of depression and cognitive fatigue (Tables 6, 7).
4. Discussion
The standardized prevalence of multiple sclerosis in Csongrád
County, Hungary is 83.7/100,000, 69% of the patients show the
relapsing-remitting clinical form (Zsíros et al., 2014), and 78% of
the relapsing-remitting patients is treated with im-
munomodulatory therapy. The 428 patients examined in our study
represent almost 10% of the Hungarian MS patients treated with
immunomodulatory therapy, and more than 50% of the Hungarian
MS patients treated with glatiramer acetate.
In this multicentre, cross-sectional study of Hungarian, relap-
sing-remitting multiple sclerosis patients treated with glatiramer
acetate, we found a considerable prevalence of fatigue and de-
pression. We also showed that these factors signiﬁcantly con-
tribute to the health-related quality of life of our patients. The
62.4% prevalence of fatigue after a mean disease duration of 11.23
years is in line with the literature data (Lerdal et al., 2003). Many
international studies found that glatiramer acetate therapy may
improve fatigue (Jongen et al., 2010, 2014; Metz et al., 2004;
Ziemssen et al., 2008).
In previous studies, the prevalence of depression among pa-
tients with multiple sclerosis was found to be 36–54% (Ziemssen,
2009). Surprisingly, in our study, the prevalence was signiﬁcantly
lower (13.4%). The risk factors for depression in multiple sclerosis
include the female gender, an age under 35 years, a family history
of major depression and stress (Patten et al., 2000). Chwastiak
et al. reported that depression correlated with a lower level of
education, a younger age and the absence of social support, while
a survey in Sarajevo, Bosnia and Herzegovina indicated that de-
pression is more frequent among younger and middle-aged pa-
tients with a higher educational level and an unmarried status
(Chwastiak et al., 2002; Alajbegovic et al., 2011). In the general
population, depression is 1.7–2 times more frequent in females
than in males (Kessler et al., 1993), however, the above-mentioned
Table 1
Hungarian multiple sclerosis centers participating in the study.
Centers No. of patients
1. Dept. of Neurol., F. Jahn Hosp. of South-Pest, Budapest,
Hungary
48
2. Dept. of Neurol., Hungarian Military Hosp., Budapest,
Hungary
3
3. Dept. of Neurol., St. István Hosp., Budapest, Hungary 4
4. Dept. of Neurol., Univ. of Debrecen, Debrecen, Hungary 25
5. Dept. of Neurol., Gy. Kenézy Hosp., Debrecen, Hungary 18
6. Dept. of Neurol., A. Petz County Hosp., Győr, Hungary 11
7. Dept. of Neurol., M. Kaposi Hosp., Kaposvár, Hungary 24
8. Dept. of Neurol., Bács-Kiskun County Hosp., Kecskemét,
Hungary
25
9. Dept. of Neurol., BAZ County Hosp., Miskolc, Hungary 21
10. Dept. of Neurol., A. Jósa Hosp., Nyíregyháza, Hungary 19
11. Dept. of Neurol., Univ. of Pécs Med. School, Pécs, Hungary 40
12. Dept. of Neurol., Univ. of Szeged, Szeged, Hungary 74
13. Dept. of Neurol., Tolna County Hosp., Szekszárd, Hungary 9
14. Dept. of Neurol., St. György Hosp., Székesfehérvár,
Hungary
16
15. Dept. of Neurol., G. Hetényi County Hosp., Szolnok,
Hungary
18
16. Dept. of Neurol., L. Markusovszky Hosp., Szombathely,
Hungary
22
17. Dept. of Neurol., K. Vaszary Hosp., Esztergom, Hungary 6
18. Dept. of Neurol., Uzsoki St. Hosp., Budapest, Hungary 38
19. Dept. of Neurol., Zs. Bajcsy Hosp., Budapest, Hungary 7
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studies did not detect this ratio in patients with MS.
The low prevalence of depression in our study may result from
the interaction of a number of factors. The majority of the re-
spondent patients were married with one or two children. How-
ever, most of the patients (about 70%) declined to answer ques-
tions about their family status. The freely available phone service
of multiple sclerosis nurses may also signiﬁcantly inﬂuence the
occurrence of depression among patients. This ensures stable and
well-functioning medical support for patients with multiple
sclerosis. The participants in this study had a relatively low med-
ian EDSS score, indicating a low level of physical disability. If in-
troduced within a few years after the onset of multiple sclerosis,
glatiramer acetate not only reduces the activity of the disease, but
may also have an antidepressant effect (Tsai, 2007; Johnson, 2012).
Our correlation analysis also demonstrated that depression
signiﬁcantly inﬂuences the health-related quality of life.
Table 2
Health-related quality of life of patients with or without fatigue.
N Mean Std. deviation Std. error
mean
t-test for equality of means t-test for equality of means
t df Sig. (2-
tailed)
Mean
difference
Std. error
difference
95% CI of the diff.
Lower Upper
“Overall, how would you rate
your own quality of life?“
No Fatigue 131 7.69 1.608 0.14 12.386 323 0.001 2.326 0.188 1.957 2.696
Fatigue 194 5.36 1.695 0.122 12.514 288.797 0.001 2.326 0.186 1.96 2.692
“Which best describes how
you feel about your life as a
whole?“
No fatigue 131 5.39 1.113 0.097 10.513 325 0.001 1.379 0.131 1.121 1.637
Fatigue 196 4.01 1.194 0.085 10.661 291.742 0.001 1.379 0.129 1.124 1.634
Overall quality of life scale % No fatigue 131 75.013 14.852 1.298 13.144 325 0.001 23.014 1.751 19.57 26.459
Fatigue 196 51.998 15.943 1.139 13.331 291.92 0.001 23.014 1.727 19.617 26.412
General health scale % No fatigue 131 65.473 20.318 1.775 15.132 325 0.001 31.441 2.078 27.353 35.528
Fatigue 196 34.032 17.021 1.216 14.613 244.674 0.001 31.441 2.152 27.203 35.679
Cognitive function scale % No fatigue 130 85.692 17.239 1.512 11.423 323 0.001 26.923 2.357 22.286 31.56
Fatigue 195 58.769 22.888 1.639 12.074 318.167 0.001 26.923 23.02 22.536 31.31
Sexual function scale % No fatigue 128 88.997 16.367 1.447 8.192 311 0.001 24.973 3.049 18.975 30.972
Fatigue 185 64.024 31.68 2.329 9.108 290.671 0.001 24.973 2.742 19.577 30.37
Bodily pain scale % No fatigue 131 82.924 21.171 1.85 12.938 323 0.001 32.913 2.544 27.908 37.918
Fatigue 194 50.01 23.347 1.676 13.185 296.503 0.001 32.913 2.496 28.001 37.826
Table 3
Correlation of the level of disability, fatigue, depression and the duration of MS with the HRQoL.
EDSS Cognitive fatigue Physical fatigue Social fatigue BDI Duration of disease
Physical functioning scale r 0.541 0.455 0.707 0.651 0.423 -0.201
p 0.0001 0.0001 0.0001 0.0001 0.0001 0.0001
Role-physical scale r 0.422 0.516 0.655 0.66 -0.452 0.209
p 0.0001 0.0001 0.0001 0.0001 0.0001 0.0001
Role-emotional scale r 0.241 0.581 0.578 0.643 0.523 0.153
p 0.0001 0.0001 0.0001 0.0001 0.0001 0.003
Bodily pain scale r 0.315 0.567 0.66 0.655 -0.478 0.138
p 0.0001 0.0001 0.0001 0.0001 0.0001 0.008
Pain scale (Vickrey) r 0.304 0.581 0.666 0.674 0.526 0.145
p 0.0001 0.0001 0.0001 0.0001 0.0001 0.005
Mental health scale r 0.181 0.556 0.569 0.649 0.716 0.047
p 0.0001 0.0001 0.0001 0.0001 0.0001 0.367
Vitality scale r 0.328 0.578 0.723 0.721 0.591 0.125n
p 0.0001 0.0001 0.0001 0.0001 0.0001 0.016
Energy scale (Vickrey) r 0.294 0.577 0.695 0.705 0.591 0.134
p 0.0001 0.0001 0.0001 0.0001 0.0001 0.01
General health scale r 0.358 0.59 0.698 0.712 0.563 0.135
p 0.0001 0.0001 0.0001 0.0001 0.0001 0.009
Social functioning scale r 0.272 0.57 0.643 0.705 0.58 -0.11n
p 0.0001 0.0001 0.0001 0.0001 0.0001 0.033
Social function scale (Vickrey) r 0.352 0.605 0.685 0.739 0.588 -0.151
p 0.0001 0.0001 0.0001 0.0001 0.0001 0.003
Cognitive function scale r 0.084 0.764 0.528 0.648 0.603 -0.057n
p 0.106 0.0001 0.0001 0.0001 0.0001 0.276
Health distress scale r 0.292 0.56 0.649 0.701 0.617 0.1n
p 0.0001 0.0001 0.0001 0.0001 0.0001 0.053
Overall quality of life scale r 0.369 0.545 0.617 0.675 0.674 0.133
p 0.0001 0.0001 0.0001 0.0001 0.0001 0.01
Sexual function scale r 0.224 0.442 0.517 0.549 0.486 0.122n
p 0.0001 0.0001 0.0001 0.0001 0.0001 0.022
Reported health transition scale r 0.262 0.273 0.412 0.387 0.317 0.143
p 0.0001 0.0001 0.0001 0.0001 0.0001 0.006
Satisfaction with sexual function scale r 0.211 0.406 0.426 0.471 0.525 0.097n
p 0.0001 0.0001 0.0001 0.0001 0.0001 0.071
Correlation is signiﬁcant at the 0.01 level (2-tailed).
n Correlation is signiﬁcant at the 0.05 level (2-tailed).
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Depression has a strong inﬂuence on all aspects of the quality of
life, and it can also mask the effects of fatigue, the EDSS score or
the duration of the disease on quality of life.
Our results suggest that it is important to diagnose depression
among multiple sclerosis patients, since depression can worsen
their health-related quality of life, and its presence can inﬂuence
the choice of immunomodulatory therapy. For patients with
multiple sclerosis, who are susceptible to depression, glatiramer
acetate is to be recommended since depression may occur as an
adverse event of interferon beta therapy.
Depression in multiple sclerosis is often not well-diagnosed,
and is not effectively treated (Marrie et al., 2009). The diagnosis is
missed in around 23–30% of the cases, and around 20–36% of the
patients are claimed to receive inadequate treatment of depression
(McGuigan and Hutchinson, 2006). The effective treatment of
depression is essential since, if left untreated, it may decrease the
level of patient compliance, which may result in the cessation of
immunomodulatory therapy.
According to several previous studies, fatigue can decrease the
health-related quality of life signiﬁcantly (Benedict et al., 2005;
Janardhan and Bakshi, 2002; Lobentanz et al., 2004; Mitchell et al.,
2005). In these studies, fatigue was examined as a one-dimen-
sional factor. Our results are partly contradictory to these ﬁndings,
which may be explained by our different approach. We examined
the three dimensions of fatigue separately, and found that physical
fatigue does not predict the quality of life of multiple sclerosis
patients. Social and cognitive fatigue, however, exerts signiﬁcantly
negative effects on the health-related quality of life. We cannot
measure these with the EDSS, and it is not sure that the patients
are willing to talk about their social difﬁculties or about their in-
ability to lead a social life due to multiple sclerosis. We have to
consider and strive to decrease the level of social fatigue, and
thereby raise the patients' quality of life perceptibly.
In the past decade, various surveys have emphasized the im-
portance of depression and fatigue in multiple sclerosis, showing
that these parameters, together with the EDSS score and the dis-
ease duration, signiﬁcantly inﬂuence the health-related quality of
life of patients with multiple sclerosis (Miller et al., 2003; Pittion-
Vouyovitch et al., 2006). Recent studies in Iran and Poland on the
Table 4
Predictors of the overall quality of life scale by linear regression.
Coefﬁcientsa
Unstandardized
coefﬁcients
Standardized
coefﬁcients
B Std.
error
Beta t Sig.
(Constant) 18.184 0.306 59.46 0.0001
Depression 0.394 0.108 0.155 3.654 0.0001
EDSS 0.057 0.029 0.152 1.947 0.052
Cognitive
fatigue
0.032 0.033 0.094 0.996 0.320
Physical
fatigue
0.148 0.023 0.785 6.329 0.0001
Social fatigue 1.742 0.478 0.152 3.643 0.0001
a Dependent variable: overall quality of life scale (N ¼ 349, R2 ¼ 0.519).
Table 5
Predictors of the overall quality of life scale among patients without or with depression by linear regression.
Coefﬁcientsa
Unstandardized coefﬁcients Standardized coefﬁcients
B Std. error Beta t Sig.
No depression (Constant) 18.287 0.312 58.698 0.0001
EDSS 0.436 0.114 0.186 3.843 0.0001
Cognitive fatigue 0.058 0.031 0.157 1.875 0.062
Physical fatigue 0.023 0.034 0.069 0.661 0.509
Social fatigue 0.143 0.025 0.768 5.780 0.0001
Depression (Constant) 14.996 2.238 6.702 0.0001
EDSS 0.102 0.384 0.046 0.264 0.793
Cognitive fatigue 0.05 0.094 0.133 0.529 0.600
Physical fatigue 0.115 0.116 0.275 0.998 0.325
Social fatigue 0.177 0.081 0.707 2.200 0.034
a Dependent variable: overall quality of life scale (N¼305 and 44, R2¼0.448 and 0.170, respectively)
Table 6
Predictors of the cognitive quality of life by linear regression.
Coefﬁcientsa
Unstandardized
coefﬁcients
Standardized
coefﬁcients
B Std.
error
Beta t Sig.
(Constant) 85.468 2.060 41.499 0.0001
Depression 10.716 3.389 0.142 3.162 0.002
EDSS 1.344 0.744 0.082 1.806 0.072
Cognitive
fatigue
27.332 2.988 0.55 9.147 0.0001
Physical
fatigue
2.642 3.693 0.051 0.715 0.475
Social fatigue 6.473 3.891 0.13 1.663 0.097
a Dependent variable: cognitive function scale % (N¼276, R2¼0.527).
Table 7
Predictors of the sexual quality of life by linear regression.
Coefﬁcientsa
Unstandardized
coefﬁcients
Standardized
coefﬁcients
B Std.
error
Beta t Sig.
(Constant) 91.62 3.077 29.774 0.0001
Depression 16.605 5.130 0.182 3.237 0.001
EDSS 1.705 1.121 0.086 1.521 0.129
Cognitive
fatigue
14.892 4.468 0.249 3.333 0.001
Physical
fatigue
0.511 5.503 0.008 0.093 0.926
Social fatigue 11.049 5.799 0.185 1.905 0.058
a Dependent variable: sexual function scale % (N¼271, R2¼0.273).
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inﬂuence of fatigue and depression on the health-related quality of
life in multiple sclerosis yielded data that are in line with our re-
sults (Kargarfard et al., 2012; Papuc and Stelmasiak, 2012).
5. Conclusions
Our study draws attention to the importance of estimation and
follow-up of both social and cognitive fatigue and depression in
multiple sclerosis. Besides the determination of the EDSS score, it
is necessary to consider these symptoms as parameters, which
inﬂuence the health-related quality of life. Their treatment adds
further values to immunomodulatory therapy, and hence provides
a better life for patients with multiple sclerosis.
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